

**The innate immune system in dendritic cell-targeted lentiviral vector immunization  
and cell-to-cell transmission of HIV-1**

Thesis by  
Jocelyn Kim

In Partial Fulfillment of the Requirements  
For the Degree of  
Doctor of Philosophy

California Institute of Technology  
Pasadena, CA

2015

(Defended December 18, 2015)

© 2015

Jocelyn Kim

All Rights Reserved

## **Acknowledgements**

I could not have set out on this adventure without the support of my family. I would like to thank my husband, Henry, who was willing to relocate in California so that I could pursue my dream of becoming a physician-scientist. In the process, we have supported one another's career goals and have had two beautiful children who we are extremely proud of. I am grateful to have such a supportive and wonderful husband. I would also like to thank my husband's parents, who have been so generous with their time. They have traveled from Korea on multiple occasions for extended periods to help care for my children so that I could continue my rigorous training in the lab. I would next like to thank my mother and father, who have been incredible parents throughout my life and during my graduate experience. I am grateful for their sacrifices and the time they have taken to fly out and watch my children so that I could attend conferences, work at the hospital, and complete my training. I would like to thank my brother, Terry, and his wife, Melissa, who have been a part of my local support system. It has been so great to have family in town that has been so supportive of my journey. I would also like to thank my sisters in Seattle, Janice and Jessica, and brother in Chicago, Billy, who have given their encourage and support throughout the years. Lastly, I would like to thank my son, Harrison, and daughter, Sabrina, who are the best children in the world. They have also supported my graduate experience, coming to lab with me so their mom could finish up experiments. They have offered a balance and aspect to my life that is truly indescribable.

I cannot thank enough my advisor David Baltimore for making my graduate experience an absolutely wonderful and transformative experience. You have taught me to cultivate and follow the questions that drive my science and passion. With your support, I have

had the time to think freely and pursue new ideas and projects of great interest. In particular, our manuscript regarding lentiviral vectors has been an exercise in following where the data takes you, disregarding preconceived notions, and thus discovering new ideas. I came to this lab to receive rigorous training, which has allowed me to think creatively, have the courage to challenge the norm, and devise clever ways to solve problems. In addition, I want to thank you and Alice for all your warmth and support as I began motherhood my graduate experience. The baby blanket you gave my son continues to be his favorite. Thank you for always understanding and respecting my priorities outside of work. As I set out on my path to become an independent scientist, I feel deeply honored to have known such a brilliant scientist and kind person, and to have received my training by you and the lab.

My thesis committee has been critical to my development as a scientist. I have to thank Otto Yang for his unwavering support over the years. Thank you for all your advice, mentorship, and driving over to Caltech for all our meetings! I would next like to thank Sarkis Mazmanian, who has provided important insight into this project and challenged me to be a better scientist. I would next like to thank Pamela Bjorkman, who has provided her vast knowledge during my graduate experience. Lastly, I would like to thank Paul Patterson, a brilliant scientist and wonderful mentor, who had always encouraged me to come to Caltech to pursue my PhD training.

I also would like to thank all the members of the Baltimore Lab who have helped with my graduate training. I have known so many great scientists and people who have made this journey possible and unforgettable. There have been so many students, post docs, technicians, scientists, and staff who have touched my life and been so encouraging throughout this process. I would like to thank Lili Yang for first helping me learn basic

molecular biology techniques, and animal work, and for providing helpful insight into experimental design. She has been a wonderful friend and role model of a woman in science. I would also like to thank Alex Sigal for his willingness to take me under his wing and teach me basic tissue culture techniques, microscopy, and ways around the lab. Along the way, you have become a great friend and I have enjoyed our discussions on science, people, and life. I have had a lot of fun in your company and laughed to tears at your Passover dinners, the breakroom, the HIV facility, and just about everywhere else. I would next like to thank Alex Balazs, who has been critical to my graduate experience. You have been a sounding board at the very beginning of this project and were instrumental in developing the idea of a platform of VLPs to identify the viral component required for immune activation. I miss our walks to Ernie's, in which we discussed just about everything including where our future paths were taking us. We have had a lot of fun at your apartment parties and will not forget karaoke night or the Magic Castle. Next, I would like to thank Alex So for his friendship and guidance throughout my time here. He has been the voice of wisdom, encouragement, and sanity when things did not always appear as if they were going to work out. I have deeply appreciated your advice on my scientific writing and clever insight regarding my science. I would next like to thank Michael Bethune, who I have learned a lot of basic techniques related to cloning and protein purification and also enjoyed our discussions on science, family, and the world. Michael is one of those great and rare people in life who you like right away, but seem to impossibly like more and more every year. Your intellect, sense of humor, kindness, and spot-on whistling will be much remembered. In addition, Yong Ouyang, aka Stella, you have been a great friend and colleague throughout my graduate career. We have a lot of discussions regarding scientific protocols and experiments as well as personal talks that have been so deep and meaningful. I would not have been able to make it through without your friendship. Lastly, I would like to thank Joanne

Laurence who has been a supportive and incredible friend in the lab. You have been so kind and caring about my graduate training and personal transition to motherhood. You have been a great friend and I am very grateful for your support.

I would also like to thank Pin Wang at USC and his laboratory for their collaborative efforts. I worked with several of his post-docs and graduate students who have been a tremendous help in my scientific training. Pin has been generous and instrumental in providing knowledge and resources on my PhD thesis.

Last but not least I would like to thank so many people in the UCLA Department of Medicine, Division of Infectious Diseases, and STAR program for their support. I would like to thank Linda Demer and Joy Frank, who are incredible woman scientists and have been so positive throughout my training. In particular, Linda, you have been such an encouraging mentor and helped me navigate my way to becoming a physician-scientist. I would also like to thank my UCLA research advisors Otto Yang and Martha Lewis, who have put considerable time into mentoring me throughout my fellowship. Next, I would like to thank Judy Currier, my chair of Infectious Diseases, and Alan Fogelman, my chair of medicine, who have been incredibly patient, generous, and supportive throughout my training.

## **Abstract**

Dendritic cells (DCs) are the sentinels of the immune system, and thus specialized in transporting foreign antigen to T cells and initiating activation of innate and adaptive immune responses. In this work, we first explore how DCs sense viral pathogens and stimulate antigen-specific T cell responses. In particular, we find the DC-targeting HIV-1 derived lentiviral vector (LV) is a potent T cell vaccine in vivo. However, the exact mechanism behind such efficient immunization is not clear. Interestingly, we find that DC activation is triggered by cellular DNA packaged in LVs and at least partially dependent on the STING protein. Innate immune activation is independent of MyD88, TRIF and IPS-1, ruling out an involvement of Toll-like receptors or RIG-I-like receptor signaling. Further, we find that antigenic protein delivered in viral particles via pseudotransduction is sufficient to stimulate an antigen-specific immune response. Delivery of the viral genome encoding the antigen increases the magnitude of this response in vivo, but is irrelevant in vitro. Thus, pseudotransduction, genomic transduction, and STING-mediated activation thus collaborate to make the DC-targeted LV a uniquely powerful immunogen. In addition, we explore how DCs mediate HIV-1 infection of T cells via cell-to-cell infection. In particular, we assess how DC-to-T cell transmission of HIV-1 allows for a concentrated amount of virus to be directed to an uninfected T cell. We report that DCs amplify the efficiency of T cell infection, resulting in anti-retroviral drug insensitivity compared to T cell infection in the absence of DCs. The DC-mediated amplification and drug-insensitivity of T cell infection are both entirely dependent on physical cellular interactions. Further, we find that the input of a virus is important to the drug insensitivity of DC-to-T cell infection, but not DC-free T cell infection. Thus, we have studied two separate roles of DCs: initiating immune responses to LVs and mediating transmission of infectious HIV-1. The study of these roles is important to discovering novel immune adjuvants and identifying targeted therapeutics to inhibit viral dissemination.

## PUBLISHED CONTENT AND CONTRIBUTIONS

The work in this thesis has not been published.

## TABLE OF CONTENTS

Title page	i
Copyright Page	ii
Acknowledgements	iii
Abstract	vii
Published Content and Contributions	viii
Table of Contents	ix
Chapter 1: Introduction to the immune system, lentivectors, and transmission of HIV-1	1
Overview of thesis	2
Overview of Dendritic Cells	2
Overview of Innate Immune Recognition of Viral Pathogens	3
Overview of cytosolic DNA sensors of the Innate Immune System	5
Overview of DC vaccines including LVs	7
Overview of cell-to-cell transmission of HIV-1	8
References	9
Table 1. List and description of human TLRs	14
Figure 1. Putative cytosolic DNA sensors	15
Figure 2. Schematic of plasmids required to generate lentivector	16
Figure 3. Mechanisms of DC-mediated HIV-1 transmission to CD4 <sup>+</sup> T cells	17
Chapter 2: Dendritic cell targeted lentivector immunotherapy	18
Abstract	19
Introduction	20
Results	22
Discussion	33
Experimental Procedures	38
Figure Legends	47
References	54
Supplemental Figure Legends	61
Figure 1. Lentivector (LV) pseudotransduction delivers proteins and stimulates dendritic cells (DCs)	63
Figure 2. LV DNA, genome, and capsid are not required for DC maturation and CD8 <sup>+</sup> T cell priming	64
Figure 3. LV activation of DCs and subsequent CD8 <sup>+</sup> T cell priming is dependent on STING, but not MyD88, TRIF, or IPS-1	65
Figure 4. Viral-like particles (VLPs) activate DCs and antigen-specific CD8 <sup>+</sup> T cells via the STING pathway	66
Figure 5. Viral fusion is required for DC activation	67
Figure 6. LV particles and VLPs contain human genomic DNA recognized by the host STING pathway	68
Figure S1. LVs pseudotransduce and activate mouse BMDCs, related to Figures 1 and 3	69
Figure S2. LVs and VLPs carry heterologous proteins, related to Figure 2	70
Figure S3. MyD88 <sup>-/-</sup> /TRIFLps2/Lps2 or MyD88 <sup>-/-</sup> /IPS-1 <sup>-/-</sup> BMDCs are fully activated by LVs, related to Figure 3	71
Figure S4. Normal T cell subsets in STING-deficient mice under non-stimulatory conditions, related to Figure 3	72
Figure S5. LV particles and VLPs contain human genomic DNA, related to Figure 6	73
Chapter 3: Dendritic cell-to-T cell infection	74
Abstract	75
Introduction	76
Results	76
Discussion	78
Experimental Procedures	80

Figure Legends .....	82
References .....	83
Supplementary Figure Legends .....	85
Figure 1. DCs significantly amplify T cell infection .....	86
Figure 2. DC-T cell infection is drug-resistant .....	87
Figure 3. DC-T cell drug resistance depends on physical contact between cells .....	88
Figure 4. DC-to-T cell transmission is dependent on the amount of virus in the system .....	89
Supplementary Figure 1. LPS activation of monocyte-derived DCs .....	90
Supplementary Figure 2. DC amplification of HIV infection of T cells in six donors .....	91
Supplementary Figure 3. DC amplification of T cell infection with different HIV-1 strains .....	92
Chapter 4: Conclusions and Future Directions .....	93
Conclusions .....	94
Significance .....	94
Innovation .....	96
Future Directions .....	96
References .....	97

## **Chapter 1**

**Chapter 1: Introduction to the immune system, lentivectors, and transmission of HIV-1**

## **Overview of thesis**

In this thesis we explore the role of dendritic cells (DCs) in regulating the adaptive immune system and mediating the anti-viral immune response to HIV-1 derived lentiviral vectors (LVs). The study of immunology and LVs is important in gaining understanding of anti-viral immunity as well as HIV-1 pathogenesis. We seek to learn how DCs can be critical to the development of efficient anti-viral immune responses, but also be culprits in aiding viral dissemination.

The first chapter will provide background information on LVs and HIV-1 and the innate immune response in mediating immunity and infection to these viral vectors. It will also discuss the role of DCs in HIV-1 dissemination. In chapter 2, we will explore in depth how LVs activate DCs and result in priming of antigen-specific memory T cells. Our findings suggest that cellular DNA may act as a viral ligand to the STING pathway. In chapter 3 we continue to explore the role of DCs in HIV-1 infection. We find DCs that amplify HIV infection of T cells. This mode of transmission is relatively resistant to reverse transcriptase inhibitors compared to T cell infection in the absence of DCs. We consider the future directions and potential implications of this work in chapter 5, and discuss ongoing work to investigate innate immune signaling pathways associated with LV and HIV recognition, viral heterogeneity, and ways to address cell-to-cell infection.

## **Overview of Dendritic Cells**

DCs are an important link between the innate and adaptive immune systems. They are derived from cells in the bone marrow and reside in tissues throughout the body, sampling the environment and processing this information for activation of the adaptive immune system. When DCs capture antigen and are activated, they will migrate to

nearby lymphoid tissues. The antigenic protein is presented on the surface of DCs on the major histocompatibility complex (MHC) to naïve T cells (Banchereau and Steinman, 1998). Activated DCs initiate the differentiation of naïve antigen-specific T cells into effector and memory T cells. Non-activated DCs can also present antigen to T cells, but without stimulation signals T cell tolerance is generated (Heath and Carbone, 2001). Thus, activation of DCs is important in regulating immune stimulation versus tolerance.

### **Overview of Innate Immune Recognition of Viral Pathogens**

DC maturation leads to the downregulation of antigen-capture activity, the increased expression of surface MHC class II molecules and co-stimulatory molecules, cytokine secretion, and migration to the draining lymph node (Trombetta and Mellman, 2005). DCs contain several families of surface and intracellular pathogen recognition receptors (PRRs), which detect a variety of conserved structures on pathogens, termed pathogen-associated molecular patterns (PAMPs), and initiate appropriate intracellular cascading activation pathways. In certain instances, host factors can be recognized as “danger” signals, when they are presented in aberrant locations or abnormal molecular complexes as a consequence of infection, inflammation, or other types of cellular stress (Beg, 2002). PRRs that are thought to be important in sensing LVs and HIV-1 include Toll-like Receptors (TLRs), Rig-I-like Receptors (RLRs), and cytosolic nucleic acid sensors.

The TLRs are the most extensively studied class of PRRs. TLRs are composed of an extracellular or luminal ligand-binding domain containing leucine-rich repeat (LRR) motifs and a cytoplasmic signaling Toll/interleukin-1 (IL-1) receptor homology (TIR) domain (O'Neill and Bowie, 2007). Ligand binding to TLRs induces receptor oligomerization, which subsequently triggers intracellular signal cascades. To date, 10 human TLRs and 13 mouse TLRs have been discovered (Mogensen, 2009). TLRs 3, 7,

8, and 9 have been implicated in sensing viral pathogens. TLR 3 recognizes dsRNA during viral replication (Alexopoulou et al., 2001); TLR 7 and 8 sense viral ssRNA (Diebold et al., 2004, Heil et al., 2004); and TLR9 senses unmethylated CpG DNA present in the virus genomes (Hemmi et al., 2000). After ligand binding, TLRs recruit the TIR domain-containing adaptor molecules, which are critical to intracellular signal transduction. MyD88 is a key adaptor molecule that is involved in signaling triggered by all TLRs, including TLRs 7, 8, and 9. However, TLR 3 is dependent on signaling via the adaptor molecule TRIF. Thus, the TLR pathways are often divided into MyD88-dependent or MyD88-independent, TRIF-dependent. Both pathways are capable of activating NF- $\kappa$ B, but may differ in their ability to induce proinflammatory cytokines and the anti-viral type I IFN response (Mogensen, 2009).

Of the RLRs, RIG-I and melanoma differentiation-associated gene 5 (MDA5) are RNA helicases that sense cytoplasmic viral RNA and stimulate Type I IFN responses. The RLRs share highly conserved domain structures, including a central DExD/H-box helicase core composed of two helicase domains with a specific insertion within Hel-2 and a C-terminal domain that confers part of the ligand specificity (Kolakofsky et al., 2012). Although similar components are shared, the RIG-I and MDA5 have distinct viral sensing roles in certain cases. For example, RIG-I has been shown to be essential in detecting paramyxoviruses and influenza virus, whereas MDA5 seems to be critical for the response to picornavirus and norovirus (Kato et al., 2006). These differences may be due to length-dependent binding and recognition of 5' triphosphate ends on dsRNA (Kato et al., 2008). However, both sensors are important in the sensing of Dengue Virus and West Nile Virus (Loo et al., 2008). The intracellular signaling downstream of RIG-I and MDA5 depends on the adaptor protein IPS-1 (also known as MAVS, CARDIF, and

VISA). The loss of IPS-1 abolishes the induction of type I IFN and proinflammatory cytokines in response to RNA viruses.

Cytosolic sensors for DNA can signal through the adaptor protein, stimulator of IFN genes (STING), which is critical for inducing Type I IFN responses. Once activated by cytosolic DNA signaling, STING stimulates TBK1 and IRF3, resulting in type I IFN response. STING can also directly detect bacterial cyclic dinucleotides (Burdette et al., 2011). The definitive cytosolic DNA sensors that signals upstream to STING have not all been identified. Currently, there are various putative cytosolic DNA sensors, which include Cyclic GMP-AMP synthase (cGAS), IFI16, DDX41, DNA-dependent protein kinases, catalytic subunit (DNA-PKcs), MRE11, and DNA-dependent activator of IRFs (DAI) (Fig. 1) (Wu and Chen, 2014). It is to be determined whether cGAS functions only in specific cell types and whether other cytosolic DNA sensors signal in conjunction with cGAS.

### **Overview of cytosolic DNA sensors of the Innate Immune System**

cGAS is activated by dsDNA through direct binding and catalyzes the production of cyclic GMP-AMP (cGAMP) from ATP and GTP. Structural analyses of cGAS show that the NTase and Mab21 domains and a unique zinc-binding motif are essential for B-form DNA binding (Civril et al., 2013). Upon direct binding of DNA, conformational changes of the NTase domain occur, allowing better access of GTP and ATP substrates required for the catalytic reactions to generate the second messenger cGAMP (Civril et al., 2013, Xiao and Fitzgerald, 2013). As a second messenger, cGAMP then activates the host STING signaling pathway. Knockdown of cGAS in mammalian cell lines abolishes Type I IFN production induced by either DNA transfection or DNA virus infection (Gao et al.,

2013). cGAS has also been shown to mediate the innate immune response to HIV and other retroviruses by detecting reverse-transcribed HIV-1 cDNA (Gao et al., 2013).

IFI16 is a DNA-binding AIM2 related protein that interacts with DNA via its two HIN domains on the C-terminus. It binds both dsDNA and ssDNA, which have both been shown to be stimulatory during lentiviral replication (Jakobsen et al., 2013). In addition, IFI16 immunoprecipitates with STING in dsDNA-stimulated THP-1 cells (Unterholzner et al., 2010). Furthermore, knockdown of IFI16 leads to decreased antiviral Type I IFN response (Kis-Toth et al., 2011). However, there is no clear mechanism for how IFI16 binds to STING. IFI16 also has a PYRIN domain and PYRIN-containing proteins usually interact with one another. STING does not have a PYRIN domain; thus, it is unclear if other proteins are involved in the IFI16-STING interaction or if the PYRIN domain is even involved in STING signaling.

DDX41 was found in a systematic RNAi screen of a family of DExD/H helicases required for induction of type I IFNs by cytosolic DNA in mouse and human cell lines (Zhang et al., 2012). The knockdown of DDX41 led to decreased type I IFN production in response to cytosolic DNA, HSV-1 and bacterial cyclic nucleotides (Zhang et al., 2012, Parvatiyar et al., 2012). In response to cytosolic DNA, DDX41 colocalizes with STING suggesting a connection with the STING signaling pathway (Parvatiyar et al., 2012). DDX41 has a DEAD domain, which is responsible for binding to DNA, but a clearly defined signaling domain that is distinct from its nucleic acid-binding domain has not been identified. Therefore, it is unclear how DDX41 recruits signaling adaptors such as STING for downstream signaling.

DNA-PKcs is an enzyme belonging to the phosphatidylinositol 3-kinase-related kinase (PI3K) protein family, which is required for the non-homologous end joining (NHEJ) pathway of DNA repair, which rejoins dsDNA breaks. This complex was identified in affinity pull-down experiments as being directly bound to dsDNA and DNA-PKcs-deficient mouse embryonic fibroblasts (MEFs) or mice showed decreased Type I IFN response to DNA virus infection (Ferguson et al., 2012).

The protein MRE11A was also found to be involved in dsDNA repair and is involved in nonhomologous joining of DNA ends. MRE11 has also been found to be a cytosolic dsDNA sensor, which signals through STING, but was not important to HSV-1 or *L. monocytogenes* anti-microbial responses (Kondo et al., 2013).

DAI was the first putative cytosolic DNA sensor found to be important to DNA-mediated induction of type I IFN response in non-immune cell lines (Takaoka et al., 2007). However, later studies found that MEFs, dendritic cells, and macrophages deficient in DAI responded normally to DNA transfection or DNA virus infection. Furthermore, DAI knockout mice showed normal immune responses to DNA vaccination (Ishii et al., 2008).

Although great progress has been made in identifying putative cytosolic DNA sensors, the exact mechanism of cytosolic DNA innate immune sensing remains unclear. It also remains to be seen how mechanisms involved in DNA damage repair overlap with viral DNA sensing pathways.

### **Overview of DC vaccines including LVs**

Since DCs are critical to eliciting innate and adaptive immune responses, vaccination strategies involving DCs are being investigated. In particular, DC vaccines are currently

being developed to stimulate tumor-specific effector and memory T cells that can clear and suppress tumor growth. In order to achieve successful DC vaccination, tumor antigens have to be processed by the DCs and maturation of DCs has to occur. For example, the ex vivo DC vaccine derives DCs from a patient, cultures them ex vivo, loads them with tumor antigens, matures them with an adjuvant, and then injects them back into the patient with the goal of eliciting tumor-specific effector T cells that induce tumor regression (Tacken et al., 2007). However, this method is labor and resource-intensive and only appropriate for a limited number of patients. In vivo targeting vaccines directly target DCs to take up antigen and become activated in vivo. This can be achieved by LVs, which are HIV-1-derived replication-defective vectors that effectively transduce dividing and non-dividing cells such as DCs. Thus, LVs are advantageous in their efficiency, manufacturability, and accessibility to a wide number of patients.

To produce LVs, a reporter gene or gene of interest is cloned into a vector sequence between the LTRs. This ensures that only the gene of interest becomes integrated into the target cell genome. The viral genes required to generate the viral capsid, matrix, envelope, and enzymes are encoded on separate vectors (Fig. 2). These vectors are on separate plasmids, to ensure the LV is replication-deficient. After the plasmids are transfected into cells, LVs can be collected in the cell supernatant.

The LV vaccine capitalizes on the ability of the vector to integrate and generate long-term gene expression. Interestingly, the persistent expression of antigen does not lead to immunotolerance, but immunostimulation without evidence of exhaustion (Karwacz et al., 2009, Obst et al., 2007). This pattern of antigen persistence leading to effective memory responses instead of immune tolerance has also been seen with other viral infections (Zammit et al., 2006, Turner et al., 2007).

Since LV vaccines are being used clinically, it is critically important to understand how they stimulate innate and adaptive immunity. The identification of the mechanisms that bestow LVs with their inherent ability to activate innate and adaptive will have great scientific and public health relevance, because it will deepen our understanding of host responses to viruses and ultimately develop effective vaccines against pathogens and cancer.

### **Overview of cell-to-cell transmission of HIV-1**

DCs also play an important role in HIV-1 infection involving activation and coordination of innate and adaptive immune responses to the virus. In addition, DCs may also play a role in the viral reservoir and dissemination via DC-mediated transmission of HIV-1 to CD4<sup>+</sup> T cells. DCs, in particular activated ones, are able to capture HIV-1 on their surface without being infected. Virus particles concentrated at or near the surface of DCs are then transmitted to uninfected target CD4<sup>+</sup> T cells via close contact in a process termed *trans*-infection (Fig. 3) (Turner et al., 2007, Coleman et al., 2013). In contrast, HIV-1 can infect DCs, productively replicate and release viral particles to new target cells in a process called *cis*-infection. However, productive infection of DCs is rare.

Host cellular molecules have been demonstrated to affect DC-mediated transmission of HIV-1 to CD4<sup>+</sup> T cells, including dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), CD4, and intercellular adhesion molecules (ICAMs). Viral factors can also affect DC-mediated transmission of HIV-1 to CD4<sup>+</sup> T cells, largely by directly interacting with and/or altering the expression of the host cell molecules. As

such, the effects of viral factors on DC-mediated transmission of HIV-1 to CD4<sup>+</sup> T cells will be described in the context of their effects on the host cell.

There are host cellular molecules and viral factors that have been demonstrated to affect DC-mediated transmission of HIV-1 to CD4<sup>+</sup> T cells. The DC-SIGN is a surface adhesion molecule highly expressed on DCs and is involved in formation of the virologic synapse and binds to HIV Env to capture the virus (Geijtenbeek et al., 2000). The blocking of DC-SIGN inhibits and the overexpression enhances DC-mediated HIV transmission. However, DC-SIGN is mainly important for HIV transmission by immature DCs (Wang et al., 2007). Another surface adhesion molecule, ICAM-1, binds to Leukocyte function-associated molecule-1 (LFA-1) expressed on the surface of CD4<sup>+</sup> T cells. The interaction of these two molecules is important to stabilization of the virologic synapse, and thus for DC-to-T cell HIV transmission (Sanders et al., 2002). The viral factors found to be important to DC-mediated viral transmission include the composition of glycosylation of the HIV Env (van Montfort et al., 2011) and Nef protein (Sol-Foulon et al., 2002).

Further exploration is required to better understand the mechanism of how the virologic synapse forms and mediates HIV transmission between cells. DC-mediated HIV-1 transmission is likely a potent mode of infection, but the implication of how this relates to drug efficacy has yet to be explored. This area needs to be further studied to develop strategies to inhibit persistent infection.

## REFERENCES

Available: <https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/>.

- ALEXOPOULOU, L., HOLT, A. C., MEDZHITOV, R. & FLAVELL, R. A. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature*, 413, 732-8.
- BANCHEREAU, J. & STEINMAN, R. M. 1998. Dendritic cells and the control of immunity. *Nature*, 392, 245-52.
- BEG, A. A. 2002. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. *Trends Immunol*, 23, 509-12.
- BURDETTE, D. L., MONROE, K. M., SOTELO-TROHA, K., IWIG, J. S., ECKERT, B., HYODO, M., HAYAKAWA, Y. & VANCE, R. E. 2011. STING is a direct innate immune sensor of cyclic di-GMP. *Nature*, 478, 515-U111.
- CIVRIL, F., DEIMLING, T., DE OLIVEIRA MANN, C. C., ABLASSER, A., MOLDT, M., WITTE, G., HORNUNG, V. & HOPFNER, K. P. 2013. Structural mechanism of cytosolic DNA sensing by cGAS. *Nature*, 498, 332-7.
- COLEMAN, C. M., ST GELAIS, C. & WU, L. 2013. Cellular and Viral Mechanisms of HIV-1 Transmission Mediated by Dendritic Cells. *Hiv Interactions with Dendritic Cells: Infection and Immunity*, 762, 109-130.
- DIEBOLD, S. S., KAISHO, T., HEMMI, H., AKIRA, S. & REIS E SOUSA, C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science*, 303, 1529-31.
- FERGUSON, B. J., MANSUR, D. S., PETERS, N. E., REN, H. & SMITH, G. L. 2012. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. *Elife*, 1, e00047.
- GAO, D., WU, J., WU, Y. T., DU, F., AROH, C., YAN, N., SUN, L. & CHEN, Z. J. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. *Science*, 341, 903-6.
- GEIJTENBEEK, T. B. H., KWON, D. S., TORENSMA, R., VAN VLIET, S. J., VAN DUIJNHOFEN, G. C. F., MIDDEL, J., CORNELISSEN, I. L. M. H. A., NOTTET, H. S. L. M., KEWALRAMANI, V. N., LITTMAN, D. R., FIGDOR, C. G. & VAN KOOYK, Y. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. *Cell*, 100, 587-597.
- HEATH, W. R. & CARBONE, F. R. 2001. Cross-presentation, dendritic cells, tolerance and immunity. *Annu Rev Immunol*, 19, 47-64.
- HEIL, F., HEMMI, H., HOCHREIN, H., AMPENBERGER, F., KIRSCHNING, C., AKIRA, S., LIPFORD, G., WAGNER, H. & BAUER, S. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science*, 303, 1526-9.
- HEMMI, H., TAKEUCHI, O., KAWAI, T., KAISHO, T., SATO, S., SANJO, H., MATSUMOTO, M., HOSHINO, K., WAGNER, H., TAKEDA, K. & AKIRA, S. 2000. A Toll-like receptor recognizes bacterial DNA. *Nature*, 408, 740-5.
- ISHII, K. J., KAWAGOE, T., KOYAMA, S., MATSUI, K., KUMAR, H., KAWAI, T., UEMATSU, S., TAKEUCHI, O., TAKESHITA, F., COBAN, C. & AKIRA, S. 2008. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. *Nature*, 451, 725-U6.
- JAKOBSEN, M. R., BAK, R. O., ANDERSEN, A., BERG, R. K., JENSEN, S. B., TENGCHUAN, J., LAUSTSEN, A., HANSEN, K., OSTERGAARD, L., FITZGERALD, K. A., XIAO, T. S., MIKKELSEN, J. G., MOGENSEN, T. H. & PALUDAN, S. R. 2013. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. *Proc Natl Acad Sci U S A*, 110, E4571-80.
- KARWACZ, K., MUKHERJEE, S., APOLONIA, L., BLUNDELL, M. P., BOUMA, G., ESCORS, D., COLLINS, M. K. & THRASHER, A. J. 2009. Nonintegrating Lentivector Vaccines Stimulate Prolonged T-Cell and Antibody Responses and Are Effective in Tumor Therapy. *Journal of Virology*, 83, 3094-3103.

- KATO, H., TAKEUCHI, O., MIKAMO-SATOH, E., HIRAI, R., KAWAI, T., MATSUSHITA, K., HIIRAGI, A., DERMODY, T. S., FUJITA, T. & AKIRA, S. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. *J Exp Med*, 205, 1601-10.
- KATO, H., TAKEUCHI, O., SATO, S., YONEYAMA, M., YAMAMOTO, M., MATSUI, K., UEMATSU, S., JUNG, A., KAWAI, T., ISHII, K. J., YAMAGUCHI, O., OTSU, K., TSUJIMURA, T., KOH, C. S., REIS E SOUSA, C., MATSUURA, Y., FUJITA, T. & AKIRA, S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature*, 441, 101-5.
- KIS-TOTH, K., SZANTO, A., THAI, T. H. & TSOKOS, G. C. 2011. Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response. *J Immunol*, 187, 1222-34.
- KOLAKOFSKY, D., KOWALINSKI, E. & CUSACK, S. 2012. A structure-based model of RIG-I activation. *RNA*, 18, 2118-27.
- KONDO, T., KOBAYASHI, J., SAITOH, T., MARUYAMA, K., ISHII, K. J., BARBER, G. N., KOMATSU, K., AKIRA, S. & KAWAI, T. 2013. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. *Proc Natl Acad Sci U S A*, 110, 2969-74.
- LOO, Y. M., FORNEK, J., CROCHET, N., BAJWA, G., PERWITASARI, O., MARTINEZ-SOBRIDO, L., AKIRA, S., GILL, M. A., GARCIA-SASTRE, A., KATZE, M. G. & GALE, M., JR. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. *J Virol*, 82, 335-45.
- MOGENSEN, T. H. 2009. Pathogen recognition and inflammatory signaling in innate immune defenses. *Clin Microbiol Rev*, 22, 240-73, Table of Contents.
- O'NEILL, L. A. & BOWIE, A. G. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nat Rev Immunol*, 7, 353-64.
- OBST, R., VAN SANTEN, H. M., MELAMED, R., KAMPHORST, A., BENOIST, C. & MATHIS, D. 2007. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. *Proceedings of the National Academy of Sciences of the United States of America*, 104, 15460-15465.
- PARVATIYAR, K., ZHANG, Z. Q., TELES, R. M., OUYANG, S. Y., JIANG, Y., IYER, S. S., ZAVER, S. A., SCHENK, M., ZENG, S., ZHONG, W. W., LIU, Z. J., MODLIN, R. L., LIU, Y. J. & CHENG, G. H. 2012. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. *Nature Immunology*, 13, 1155-+.
- SANDERS, R. W., DE JONG, E. C., BALDWIN, C. E., SCHUITEMAKER, J. H., KAPSENBERG, M. L. & BERKHOUT, B. 2002. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. *J Virol*, 76, 7812-21.
- SOL-FOULON, N., MORIS, A., NOBILE, C., BOCCACCIO, C., ENGERING, A., ABASTADO, J. P., HEARD, J. M., VAN KOOYK, Y. & SCHWARTZ, O. 2002. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. *Immunity*, 16, 145-55.
- TACKEN, P. J., DE VRIES, I. J. M., TORENSMA, R. & FIGDOR, C. G. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. *Nature Reviews Immunology*, 7, 790-802.
- TAKAOKA, A., WANG, Z., CHOI, M. K., YANAI, H., NEGISHI, H., BAN, T., LU, Y., MIYAGISHI, M., KODAMA, T., HONDA, K., OHBA, Y. & TANIGUCHI, T. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature*, 448, 501-U14.

- TROMBETTA, E. S. & MELLMAN, I. 2005. Cell biology of antigen processing in vitro and in vivo. *Annu Rev Immunol*, 23, 975-1028.
- TURNER, D. L., CAULEY, L. S., KHANNA, K. M. & LEFRANCOIS, L. 2007. Persistent antigen presentation after acute vesicular stomatitis virus infection. *Journal of Virology*, 81, 2039-2046.
- UNTERHOLZNER, L., KEATING, S. E., BARAN, M., HORAN, K. A., JENSEN, S. B., SHARMA, S., SIROIS, C. M., JIN, T., LATZ, E., XIAO, T. S., FITZGERALD, K. A., PALUDAN, S. R. & BOWIE, A. G. 2010. IFI16 is an innate immune sensor for intracellular DNA. *Nat Immunol*, 11, 997-1004.
- VAN MONTFORT, T., EGGINK, D., BOOT, M., TUEN, M., HIOE, C. E., BERKHOUT, B. & SANDERS, R. W. 2011. HIV-1 N-Glycan Composition Governs a Balance between Dendritic Cell-Mediated Viral Transmission and Antigen Presentation. *Journal of Immunology*, 187, 4676-4685.
- WANG, J. H., JANAS, A. M., OLSON, W. J. & WU, L. 2007. Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. *J Virol*, 81, 8933-43.
- WU, J. X. & CHEN, Z. J. 2014. Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids. *Annual Review of Immunology*, Vol 32, 32, 461-488.
- XIAO, T. S. & FITZGERALD, K. A. 2013. The cGAS-STING pathway for DNA sensing. *Mol Cell*, 51, 135-9.
- ZAMMIT, D. J., TURNER, D. L., KLONOWSKI, K. D., LEFRANCOIS, L. & CAULEY, L. S. 2006. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. *Immunity*, 24, 439-449.
- ZHANG, Z. Q., YUAN, B., BAO, M. S., LU, N., KIM, T. & LIU, Y. J. 2012. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells (vol 12, pg 959, 2011). *Nature Immunology*, 13, 196-196.

Receptor	Cellular localization	Microbial component(s)	Origin(s)
<b>TLRs</b>			
TLR1/TLR2	Cell surface	Triacyl lipopeptides	Bacteria
TLR2/TLR6	Cell surface	Diacyl lipopeptides Lipoteichoic acid	<i>Mycoplasma</i> Gram-positive bacteria
TLR2	Cell surface	Lipoproteins Peptidoglycan Lipoarabinomannan Porins Envelope glycoproteins GPI-mucin Phospholipomannan Zymosan $\beta$ -Glycan	Various pathogens Gram-positive and -negative bacteria Mycobacteria <i>Neisseria</i> Viruses (e.g., measles virus, HSV, cytomegalovirus) Protozoa <i>Candida</i> Fungi Fungi
TLR3	Cell surface/endosomes	dsRNA	Viruses
TLR4	Cell surface	LPS Envelope glycoproteins Glycoinositolphospholipids Mannan HSP70	Gram-negative bacteria Viruses (e.g., RSV) Protozoa <i>Candida</i> Host
TLR5	Cell surface	Flagellin	Flagellated bacteria
TLR7/8	Endosome	ssRNA	RNA viruses
TLR9	Endosome	CpG DNA	Viruses, bacteria, protozoa

Table 1. List and description of human TLRs.




Figure 1. Putative cytosolic DNA sensors.




Figure 2. Schematic of plasmids required to generate lentivector (LV).




Figure 3. Mechanisms of DC-mediated HIV-1 transmission to CD4<sup>+</sup> T cells.

## Chapter 2

### **Chapter 2: Dendritic cell-targeted lentiviral vector immunization utilizes pseudotransduction and DNA-mediated STING activation**

Published as: Jocelyn T. Kim, Yarong Liu, Rajan P. Kulkarni, Kevin K. Lee, Bingbing Dai, Geoffrey Lovely, Yang Ouyang, Pin Wang, Lili Yang, David Baltimore (2015). Dendritic cell-targeted lentiviral vector immunization utilizes pseudotransduction and DNA-mediated STING activation. *In review*.

## **ABSTRACT**

Dendritic cell (DC)-targeted lentiviral vectors (LVs) deliver antigen and innate stimulation *in vivo*, resulting in strong T cell immunization. Here, we report that DC activation is triggered by cellular DNA packaged in LVs and is at least partially dependent on the STING protein. Activation is independent of MyD88, TRIF, and IPS-1, ruling out an involvement of Toll-like receptors or RIG-I-like receptor signaling. Further, we find that antigenic protein delivered in viral particles via pseudotransduction is sufficient to stimulate an antigen-specific immune response. Delivery of the viral genome encoding the antigen increases the magnitude of this response *in vivo*, but is irrelevant *in vitro*. Pseudotransduction, genomic transduction, and STING-mediated activation thus collaborate to make the DC-targeted LV a uniquely powerful immunogen.

## INTRODUCTION

Dendritic cells (DCs) are critical to stimulating adaptive immune responses owing to their superior ability to process antigens and present them to T cells. Methods have been devised to directly target antigen to DCs for immunization purposes. One effective strategy uses an HIV-1-derived lentiviral vector (LV) to deliver genes encoding antigen to DCs as a T cell vaccine. LV can also target DCs by pseudotyping the vector with a mutant Sindbis virus glycoprotein (SVGmu), which binds to the DC-specific receptor DC-SIGN. The *in vivo* administration of this DC-targeted LV results in the selective expression of antigen in DCs and efficient priming of antigen-specific CD8<sup>+</sup> T cells with potent anti-tumor immunity in mice that out-performs conventional methods using recombinant protein antigen or adoptive transfer of antigen-loaded or viral vector-transduced DCs ([Yang et al., 2008](#), [Dai et al., 2009](#)). Recent work has shown that this form of DC immunization is also effective in humans ([Somaiah, 2015](#), [Odegard et al., 2015](#)). However, the exact mechanism behind such efficient immunization is not clear. It is evident that antigen delivery methods that lack a DC maturation signal — such as antigen conjugated to the DC-specific anti-DEC-205 antibody — lead to effective antigen presentation but promote tolerance rather than immunity ([Bonifaz et al., 2002](#)). The co-administration of anti-CD40 as a maturation stimulus is required to break immune tolerance. Thus, the success of DC-targeted LV immunization likely requires the coupling of two independent functions: delivery of antigen and activation of DCs.

The first function — antigen delivery to DCs — is thought to primarily occur by LV transduction ([Cowan et al., 2002](#)). However, transduction of differentiated DCs *in vitro* is notoriously difficult due to the host restriction factor SAMHD-1, which blocks reverse transcription ([Manel et al., 2010](#)). The transduction of early stage or precursor DCs is more easily achieved, but these cells are not typically stimulated by the infection process

([Dyall et al., 2001](#), [He et al., 2005](#), [Chinnasamy et al., 2000](#), [Schroers et al., 2000](#), [Breckpot et al., 2007](#), [Rouas et al., 2002](#), [Breckpot et al., 2003](#), [Arce et al., 2009](#)). Thus, it is not clear how LVs can concurrently deliver antigen and stimulate target DCs. One possibility is that another mechanism of protein antigen delivery exists besides transduction. For example, pseudotransduction is a process by which antigen expressed by the producer cells is carried by the vector into target cells ([Haas et al., 2000](#), [Nash and Lever, 2004](#), [Breckpot et al., 2007](#)). It is unknown if LV pseudotransduction plays a significant role in either antigen delivery and immune stimulation.

The second function — stimulation of DCs — is expected to occur through the triggering of host intracellular innate immune sensing pathways. Differentiated DCs are well activated by the LV transduction process ([Yang et al., 2008](#), [Dyall et al., 2001](#), [Breckpot et al., 2010](#), [Metharom et al., 2001](#), [He et al., 2005](#)). LV nucleic acids trigger endosomal Toll-like receptors (TLRs), which signal through the adaptor molecules MyD88 and/or TRIF ([Breckpot et al., 2007](#), [Beignon et al., 2005](#), [Pichlmair et al., 2007](#), [Breckpot et al., 2010](#)). RNA helicase Rig-I-like receptors (RLRs), which signal through IPS-1 (also known as Cardif, MAVS, and VISA), detect cytosolic HIV genomic RNA ([Berg et al., 2012](#)). Finally, various cytosolic DNA sensors signal through the adaptor molecule STING (also known as TMEM173, MYPS, MITA and ERIS), and are involved in the detection of reverse transcribed lentiviral DNA ([Jakobsen et al., 2013](#), [Gao et al., 2013](#)). However, it is not clear which of the LV components and intracellular innate immune detection pathways is critical to DC activation and subsequent development of adaptive immunity.

Here we report LV pseudotransduction, a process by which antigen expressed by the producer cells is carried by the vector into target cells, contributes to antigen delivery, and is the primary mechanism of immune stimulation. LV transduction contributes to antigen delivery in vivo, but is not required for immune stimulation. In addition, LVs induced DC activation via the host STING pathway, independent of TLR and RLR signaling. We found encapsulated human genomic DNA is a previously unidentified constituent of virion preparations that can be recognized by the cytosolic DNA-sensing STING pathway.

## **RESULTS**

### **LVs pseudotransduce DCs via protein delivery**

We first sought to understand the mechanism of antigen delivery to differentiated DCs by LVs. We differentiated DCs by culturing mouse bone marrow cells and human monocytes in media containing the appropriate cytokines for eight days. We then treated these differentiated DCs with vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped LV expressing green fluorescent protein (GFP) at a multiplicity of infection (MOI) of one. The LV-treated DCs expressed a low but significant level of GFP by flow cytometry (**Figures S1A** and **S1C**), which was undiminished by reverse transcriptase inhibitors (RTIs) (**Figures 1A** and **1B**). By contrast, 293T cells treated with the same dose of LVs were efficiently transduced, as evidenced by a higher level of GFP expression, which was sensitive to RTIs (**Figures 1A** and **1B**). The expression of GFP in DCs was highest immediately after LV treatment and then steadily decreased over 48 h (**Figure S1C**). In addition, we found that the protein synthesis inhibitor cycloheximide failed to decrease GFP expression, indicating that the GFP detected immediately after LV treatment was not produced de novo (**Figure 1C**). We also detected the protein GFP in LV lysate by Western blot analysis (**Figure 1D**), which indicated the presence of

approximately one microgram of GFP per microgram of p24 by enzyme-linked immunosorbent assay (ELISA) (data not shown). This ability of LVs to incorporate vector-encoded protein was not specific to GFP because we also detected ovalbumin (OVA) in the lysate of LV encoding OVA (**Figure S2A**). These results are consistent with previous reports, indicating that LVs carry protein ([Haas et al., 2000](#), [Nash and Lever, 2004](#), [Breckpot et al., 2007](#)) and poorly transduce differentiated DCs in vitro ([Schroers et al., 2000](#), [Metharom et al., 2001](#), [He et al., 2005](#), [Manel et al., 2010](#)). Retroviral particles have been found to carry cellular mRNA ([Galla et al., 2004](#)) and bacterial plasmids ([Pichlmair et al., 2007](#)), which could contribute to GFP expression in the target cell. However, since the GFP expression was insensitive to cycloheximide (**Figure 1C**), this suggests that GFP was not generated de novo in the DC, but likely delivered via pseudotransduction.

### **LV pseudotransduction of DCs induces activation**

We next sought to determine whether LV pseudotransduction resulted in activation of differentiated DCs. We observed LV pseudotransduced mouse bone marrow derived DCs (BMDCs) were activated similarly to LPS treatment (**Figure S1B**). This activation was not diminished by RTIs, as demonstrated by the undiminished expression of DC activation markers CD86 and mouse MHCII molecule I-Ab (**Figure 1E**). LV pseudotransduced human monocyte-derived DCs (moDCs) were also activated and unaffected by RTIs (**Figure 1F**). This lack of sensitivity to RTIs was not due to ineffective inhibition of reverse transcription because the RTIs significantly blocked GFP transduction in LV-infected 293T cells (**Figure 1A and 1B**). These results suggest that LV pseudotransduced DCs are activated by a reverse transcriptase-independent mechanism.

### **Viral envelope is an important immunostimulatory component**

Next, we sought to systematically determine the LV component responsible for DC activation. We generated a platform of genome-less VLPs by exploiting the modularity of the LV system and omitted plasmids encoding the viral genome, capsid or envelope (**Figure 2A**) ([Pichlmair et al., 2007](#), [Mangeot et al., 2011](#)). We confirmed the presence or absence of the viral envelope and capsid in these VLPs by Western blot analysis for VSV-G and p24 (**Figure 2B**). Similar to LVs, we found that pseudotyped VLPs incorporated vector-encoded proteins such as GFP or OVA (**Figures 2B** and **S2B**). However, “bald” viral particles, which were produced by transfecting 293T producer cells with the LV packaging plasmids encoding *gag*, *pol*, and *rev* ([Cowan et al., 2002](#)), were not capable of incorporating vector-encoded proteins. We next assessed whether these proteins were carried within the VLP or associated externally. We pre-treated VLP incorporating OVA with proteinase K, and then inactivated the proteinase K with phenylmethylsulfonyl fluoride (PMSF) before lysis of the particles, and still detected OVA in the VLP lysate, indicating that OVA was carried within the VLP (**Figure S2C**). If the proteinase K was not inactivated prior to particle lysis, OVA was no longer detected. We next determined whether VLPs were capable of delivering vector-encoded proteins to DCs. We observed the VSV-G or SVGmu envelope was required for VLPs to deliver GFP into mouse BMDCs and human moDCs (**Figure 2C**). In addition, pseudotyped VLPs, but not “bald” VLPs, induced activation of DCs (**Figure 2D**). The inclusion of the vector genome or viral capsid had no effect on DC activation. Also, VLPs lacking the viral genome and capsid efficiently activated human moDCs (**Figure 2E**). Altogether these data suggest that the viral envelope, but not the vector genome or capsid, was necessary and sufficient to activate DCs.

### **LV genome, cDNA, and capsid are not required for immune stimulation in vivo**

To determine whether these findings were relevant in vivo, we examined whether reverse transcription and the LV genome were required for LV immunization. Prior work demonstrated that LV expressing OVA and pseudotyped with SVGmu (LV-OVA) was DC-specific and elicited potent OVA-specific CD8<sup>+</sup> T cell responses ([Yang et al., 2008](#)). We injected the DC-targeted LV-OVA into mice with or without a concurrent oral regimen of RTIs. The administration of these RTIs was initiated one week prior to LV-OVA immunization and continued throughout the experiment. To determine the importance of the viral genome, we immunized mice with VLP carrying OVA pseudotyped with SVGmu (VLP-OVA). Both the LV-OVA and VLP-OVA used in this experiment carried OVA protein, the viral capsid, and the SVGmu envelope, but only the LV carried the viral genome. We pseudotyped all vectors used for immunization with the SVGmu envelope to limit off-target cell effects. We initially found OVA-specific effector memory CD8<sup>+</sup> T cells were similarly induced in mice treated with LV-OVA with or without RTIs or VLP-OVA at seven days post-immunization (**Figure 2F** top row). However, through ten days post-immunization, the magnitude of the OVA-specific CD8<sup>+</sup> T cells continued to increase in LV-immunized mice, but not in the LV-OVA with RTIs or VLP-immunized mice (**Figure 2F** bottom row). After a second administration of homologous vector, the secondary OVA-specific CD8<sup>+</sup> T cell responses demonstrated more rapid kinetics and higher magnitudes than the primary immune response in all three groups (**Figure 2G**). In addition, these OVA-specific CD8<sup>+</sup> T cells expressed similar effector memory phenotypes (CD62L<sup>lo</sup>CD44<sup>hi</sup>) in all three groups (**Figure 2H**). The primary and secondary immunization responses were similar between the mice receiving LV with RTIs and VLP, suggesting that a component of LV immunization is independent of reverse transcription and the viral genome, thus, likely due to pseudotransduction.

After the secondary immune responses subsided, we next assessed the *in vivo* function of the prime-boosted CD8<sup>+</sup> T cell responses using an OVA-expressing tumor model. We injected OVA-expressing tumor cells and control non-OVA-expressing tumor cells on opposing legs, enabling intra-animal comparison. Mice homologously primed and boosted with LV with or without RTIs or VLPs were effectively protected against the growth of OVA-expressing tumors (**Figure 2I**). The non-OVA-expressing tumor cells continued to grow in the mice as expected. The efficient anti-tumor protection of LV with RTI and VLP-immunized mice is not altogether surprising since 8-10% of the CD8<sup>+</sup> T cells were OVA-specific after the boost. Therefore, the vector genome and its transduction enhanced, but were not necessary to inducing memory CD8<sup>+</sup> T cells. These results suggest that LV pseudotransduction is sufficient to induce a functional memory CD8<sup>+</sup> T cell response.

To investigate the immunostimulatory effect of the viral capsid and envelope we homologously prime-boosted mice with VLPs carrying OVA with or without the viral capsid (VLP-OVA or VLP-OVA $\Delta$ gag, respectively). Both immunization groups developed similar primary and secondary CD8<sup>+</sup> T cell responses and were effectively protected against the growth of OVA-expressing tumors (**Figures 2J** and **2K**). Therefore, VLPs, which have the viral envelope as the sole viral component, generated a sufficiently strong memory CD8<sup>+</sup> T cell response protective against the growth of OVA-expressing tumor cells. The viral capsid did not enhance immunization responses. Thus, the viral envelope of the vector is sufficient in stimulating LV immunization responses *in vivo*.

### **LV transduction enhances antigen delivery**

We next aimed to understand why LV immunization generated a higher magnitude of memory CD8<sup>+</sup> T cells compared to LV with RTI or VLP immunizations. We hypothesized that LV transduction contributes to antigen delivery rather than immune stimulation. We generated an SVGmu-pseudotyped LV encoding GFP and carrying the protein OVA (LV-GFP<sup>gene</sup>-OVA<sup>protein</sup>) by transiently transfection of 293T cells with the plasmids required to produce GFP-expressing LV and an expression plasmid for OVA. Because the vector in these virions did not encode OVA, the OVA-specific CD8<sup>+</sup> T cells induced would be a result of LV pseudotransduction. Additionally, because this vector was capable of reverse transcription, it would indicate if reverse transcribed LV DNA was an immune adjuvant. This vector induced an OVA-specific CD8<sup>+</sup> T cell response similar to VLP-immunized mice (**Figure 2L**), suggesting that reverse transcribed LV DNA itself is not an immune adjuvant to the antigen-specific CD8<sup>+</sup> T cell response produced by pseudovirions. There should not be antigenic competition between GFP and OVA because GFP is minimally antigenic and fails to elicit a GFP-specific CD8<sup>+</sup> T response in C57/B6 mice ([Skelton et al., 2001](#)). Thus, this data suggests antigen delivery during LV immunization is an additive process between pseudotransduction and transduction. However, LV genome transduction does not appear to contribute to immune stimulation.

### **LVs activate DCs and adaptive immunity via STING pathway**

We next set out to identify the innate immune signaling pathway responsible for LV detection, DC maturation, and subsequent priming of CD8<sup>+</sup> T cells. We treated BMDCs from mice deficient in MyD88, TRIF, or IPS-1 with an LV expressing GFP pseudotyped with VSV-G or SVGmu. Consistent with prior work, we found that the two vectors, VSV-G and SVGmu-pseudotyped LVs, similarly activated wild-type BMDCs (**Figure S1**). We observed that LVs capably activated BMDCs from mice deficient in MyD88, TRIF, or IPS-1 (**Figure 3A**). To examine the possibility of redundant pathways, we treated

BMDCs from mice doubly deficient in MyD88 and TRIF or MyD88 and IPS-1 with LV and found that DC activation was still unaffected (**Figures S3A and S3B**). To study activation of DCs in vivo we injected the DC-targeted LV-OVA into mice deficient in MyD88, TRIF, or IPS-1 and measured OVA-specific CD8<sup>+</sup> T cells. We found that OVA-specific effector memory CD8<sup>+</sup> T cells fully developed in mice deficient in MyD88, TRIF, or IPS-1 at similar levels to wild-type mice (**Figures 3B-3E**). These findings suggest that LV innate immune detection and subsequent adaptive immunity do not depend on TLR and RLR signaling pathways.

We turned to the STING-signaling pathway, an important adaptor protein involved in cytosolic viral DNA sensing. To address whether STING was important in LV detection, we injected STING-deficient mice with the DC-targeted LV-OVA and found a significantly diminished OVA-specific CD8<sup>+</sup> T cell response compared to wild-type mice immunized with LV-OVA (**Figures 3E and 3F**). Consistent with other work, we noted normal T cell subsets in unimmunized STING-deficient mice (**Figure S4**) ([Ishikawa et al., 2009](#)). These results indicate that LV activation of DCs and CD8<sup>+</sup> T cell response is partially dependent on STING.

#### **VLPs activate DCs and adaptive immunity via STING pathway**

We next investigated whether the reverse transcribed LV DNA was required to induce the STING-dependent immune response. We infected mouse BMDCs from STING-deficient mice with VSV-G or SVGmu-pseudotyped VLP carrying GFP and found that maturation was partially dependent on STING (**Figure 4A**), suggesting a component other than the viral genome could activate STING. In addition, STING-deficient BMDCs treated with VLP carrying OVA had a reduced ability to activate OT-1 CD8<sup>+</sup> T cells, which express an OVA-specific TCR, as demonstrated by the reduced expression of T

cell activation surface markers, CD69 and CD25 (**Figure 4B**). We next treated STING-deficient mice with a homologous prime-boost vaccination of the DC-targeted VLP-OVA, which lacked the LV genome and capsid, and observed significantly less effector memory CD8<sup>+</sup> T cells in the STING-deficient mice (**Figures 4C-4E**). Altogether, these results demonstrate that a component other than the lentiviral genome or reverse transcribed LV DNA can trigger the host STING pathway.

### **Viral fusion is required for DC activation**

Since we found that the viral envelope was necessary and sufficient for stimulating DCs, we next focused on understanding this mechanism of activation. The viral envelopes of vesicular stomatitis virus and Sindbis virus induce cell-surface receptor mediated endocytosis and release viral contents into the cytosol through pH-dependent viral fusion between the viral envelope and host endosomal membrane ([Florkiewicz and Rose, 1984](#), [Smit et al., 1999](#)). To investigate the importance of viral fusion on DC activation, we treated mouse BMDCs with pseudotyped VLPs devoid of the LV genome and capsid or LVs in the presence of the fusion inhibitor chloroquine ([Dille and Johnson, 1982](#)). We observed that DC activation by VLPs and LVs was abolished in the presence of chloroquine (**Figure 5A**). This effect was not due to lack of internalization because intracellular punctate GFP was evident in the chloroquine-treated cells (**Figure 5B**). We next used an altered VSV-G, in which mutations rendered the protein fusion-defective without altering envelope binding or receptor-mediated endocytosis ([Zhang and Ghosh, 1994](#)). BMDCs treated with fusion-competent VLP displayed diffuse intracellular GFP presence by microscopy, whereas DCs treated with the fusion-defective VLP showed punctate GFP presence similar to chloroquine-treated cells (**Figure 5B**). We also observed the fusion-defective LV and VLP failed to activate mouse BMDCs (**Figure 5C**).

Thus, these findings suggest that viral fusion is required for LV and VLP activation of DCs.

We next asked whether the viral process of membrane fusion itself and/or the release of a putative activating component into the cytosol represented the activating stimuli. To first determine whether VSV-G-mediated fusion itself was immunostimulatory we incorporated VSV-G into the lipid membrane of non-cationic multilamellar liposomes, which allows for the liposomal contents to evade lysosomal degradation and be delivered into the cytosol via viral envelope-directed fusion ([Abe et al., 1998](#)). Indeed, we observed that delivery of GFP into mouse BMDCs by GFP-carrying liposomes was greatly enhanced if the liposomes were enveloped with VSV-G (**Figure 5D**). Additionally, maturation of DCs was increased if liposomes were enveloped with VSV-G, suggesting that VSV-G-directed fusion was immunostimulatory. To determine whether VSV-G-directed fusion induced DC activation via STING, we treated STING-deficient mouse BMDCs with VSV-G liposomes and found that DC maturation was unaffected (**Figure 5E**). These results suggest that VSV-G-directed fusion itself induces DC activation in a STING-independent manner. Thus, there appears to be two separate activating processes at work when enveloped particles stimulate DCs: one is STING-dependent and the other is STING-independent. These findings suggest the STING-independent process is activated by envelope protein-directed fusion. What then activates the STING-dependent process? It seemed likely that a stimulatory viral component was released into the cytoplasm by viral fusion.

### **Lentiviral particles and VLPs contain human DNA**

We next attempted to identify an immunostimulatory component that might be released by LVs or VLPs. Since STING is involved in cytosolic dsDNA recognition, we suspected

that LVs and VLPs might contain non-viral DNA. Indeed, plasmid DNA used during LV production has been detected inside LV particles ([Pichlmair et al., 2007](#)). Consistent with this work, we amplified plasmid-specific DNA sequences of the VSV-G and ampicillin resistance genes in the LV and VLP preparations by PCR. Interestingly, we also amplified DNA sequences for human beta-actin and human Alu repeat element in LV and VLP preparations (**Figures 6A, S5A, and S5B**). We did not find evidence of human DNA in cell-free supernatant collected from 293T cells transfected with a mock plasmid (**Figures 6A and S5B**). To assess whether the plasmid and human DNA were carried within or associated externally to the particles, we pre-treated VLPs with DNase I to degrade external DNA, and then inactivated DNase I with EDTA before particles were lysed and then analyzed by PCR. Despite pre-treatment with DNase I, we continued to detect plasmid and human DNA in the vector preparations, suggesting plasmid and human DNA was contained within the particles (**Figure 6B**). We used genomic DNA to show DNase I digestion was efficient and DNase I inactivation with EDTA was effective (**Figure 6C**). We also amplified plasmid and human DNA in the cell-free supernatant of 293T cells transfected with a plasmid encoding HIV-1 (**Figure 6D**). Therefore, these results suggest that LV, VLP, and infectious HIV-1 particles, which are produced by transient transfection of 293T cells, contain both plasmid and human genomic DNA.

To determine whether the presence of DNA in particles was particular to material made in 293T cells, we asked whether HIV-1 passaged in human PBMCs also contained human genomic DNA. Interestingly, we were able to amplify human DNA from the cell-free HIV-1 supernatant collected after passage the virus in human PBMCs (**Figures 6E**). Human DNA was not detected in the cell-free supernatant collected from uninfected PBMCs. In addition, we found that the DNA detected in the passaged cell-free HIV-1

supernatant was resistant to DNase I (**Figure 6F**), suggesting that human genomic DNA was also encapsulated inside HIV-1 particles.

### **Human DNA delivered into DCs by VSV-G fusion is immunostimulatory**

We next questioned whether the delivery of plasmid or genomic DNA by viral fusion would enhance the DC activation generated by viral fusion itself. Therefore, we exposed mouse BMDCs to empty VSV-G liposomes or VSV-G liposomes carrying plasmid DNA or genomic DNA extracted from 293T cells. As expected, we found VSV-G liposomes induced DC maturation (**Figure 6G**). The addition of human genomic DNA into VSV-G liposomes resulted in even higher levels of DC activation. We then found that the enhancement in DC activation due to human DNA was abrogated in STING-deficient BMDCs (**Figure 6H**). These results suggest that both viral fusion itself and viral-fusion-dependent delivery of human DNA are able to induce DC maturation, the former in a STING-independent and the latter in a STING-dependent manner. These findings provide an explanation for the STING-dependence observed in the innate and adaptive immune responses generated by LVs and VLPs.

## **DISCUSSION**

From our previous work we knew that DC-targeted LVs deliver antigen to DCs and stimulate a massive antigen-specific CD8<sup>+</sup> T cell response in vivo ([Yang et al., 2008](#)), which was consistent with previous work demonstrating LVs activate innate and adaptive immunity ([Granelli-Piperno et al., 2000](#), [He et al., 2005](#), [Dullaers et al., 2006](#), [Esslinger et al., 2003](#)). In the present investigation, we examined why LVs are so effective at these processes. We were especially interested in understanding how these vectors deliver antigen and provide immune stimulation. We found that there were four components of the virions contributing to the immunization process.

First, we found that vector-encoded protein antigen is carried over from the producer cells in the vector particles via pseudotransduction. Previous reports of pseudotransduction ([Haas et al., 2000](#), [Nash and Lever, 2004](#), [Breckpot et al., 2007](#)) have not appreciated how effectively this process delivers antigen to differentiated DCs. We observed that the in vivo administrations of DC-targeted LV in the presence of RTIs and VLP immunization were sufficient in producing antigen-specific CD8<sup>+</sup> T cells, suggesting LV pseudotransduction alone capably delivers antigen and simulates the immune system.

Second, we found that the delivery of the LV genome was important to antigen expression, but not immune stimulation. Mice immunized with a LV encoding GFP and carrying the protein OVA (LV-GFP<sup>gene</sup>-OVA<sup>protein</sup>) had similar immune responses to VLP-OVA immunized mice. These results strongly imply that the viral genome of the LVs, in the form of reverse transcribed DNA, encodes antigen and contributes to antigen delivery, but not to immune stimulation. This is consistent with our in vitro results showing virtually all of the antigenic stimulation of differentiated DCs is due to pseudotransduction because activation is not sensitive to RTIs and efficiently occurs with viral genome-deficient vectors. The cells transduced by our DC-targeting LV in vivo may be early stage DCs, which are relatively easier to transduce, but resistant to stimulation compared to differentiated DCs ([Chinnasamy et al., 2000](#), [Rouas et al., 2002](#), [He et al., 2005](#), [Schroers et al., 2000](#)). The mechanism of how transduced cells contribute to antigen delivery has yet to be defined. Since our data and previous work suggest that LV transduction is not stimulatory, it is possible that antigen in transduced cells may be indirectly presented or cross-presented to the immune system ([He and Faló, 2007](#)). Altogether, our results further clarify the role of true LV infection in vivo.

Third, we found that the activation of DCs (assayed by the appearance of activation marker proteins on the cell surface) was partly a consequence of fusion between the LV membrane and the endosomal membrane. We showed that particles must be internalized (bald particles were ineffective) and then fused with endosomal membranes (active viral fusogen is needed and chloroquine, which inhibits endosome acidification, or fusion-defective vectors abolish DC activation). This process did not require STING, an endoplasmic reticulum-resident protein and adaptor protein for cytosolic DNA detection pathways.

Fourth, we investigated what other mechanisms might be involved in DC activation. By using various knockouts, we found that neither a TLR nor RIG-I was involved. Rather, DC activation was partially dependent on STING. Our study identified cellular DNA packaged from producer cells as the component of the virion that is sensed by STING. This is consistent with previous reports showing cytosolic dsDNA is a well-known activator of innate immunity through STING (and cyclic GMP-AMP synthase (cGAS)) ([Gao et al., 2013](#), [Jakobsen et al., 2013](#)). Thus, the fourth component of the virion that contributes to LV immunization is encapsulated human DNA. Current work is underway to examine the role of cGAS, which recognizes cytosolic dsDNA and signals upstream of STING ([Sun et al., 2013](#)).

Our study sheds new light the mechanism of DC vaccination by LVs. We have found that antigen delivery is an additive process between LV pseudotransduction and transduction. However, LV immune stimulation is induced primarily by LV pseudotransduction. We had expected that TLR or RIG-I activation of innate immune responses was important based on previous work suggesting the importance of MyD88

and TRIF in DC activation in vitro and in vivo ([Breckpot et al., 2007](#), [Pichlmair et al., 2007](#)). However, we found that neither TLR nor RIG-I signaling was involved. Rather, activation was partially dependent on STING. The differing results of our study may be because we injected a DC-targeted LV into mice to determine the direct effects of LVs on DCs in vivo. Previous work used adoptive transfer experiments to infer the in vivo effect of LVs on DC activation ([Breckpot et al., 2007](#), [Pichlmair et al., 2007](#)). In addition, we found viral fusion itself and viral-fusion-dependent delivery of human DNA induced DC maturation, the former in a STING-independent and the latter in a STING-dependent manner. One group has also observed that STING was required to generate type I interferon responses to the fusion ([Holm et al., 2012](#)) by herpes VLPs and cationic liposomes. Herpes VLPs have different mechanisms of entry compared to our VSV-G and SVGmu-pseudotyped VLPs. Additionally, the mechanism of entry of cationic liposomes is not fully elucidated and does not follow classical fusion utilized by enveloped viruses ([Elouahabi and Ruyschaert, 2005](#)). Thus, we used VSV-G enveloped liposomes to study viral fusion itself.

Our findings raise important questions regarding the nature of particles in virus preparations. Previous work has suggested that HIV particles passaged in T cells are a mixture of replication-competent and replication-defective particles, the latter being more abundant ([Bernier and Tremblay, 1995](#)). In addition, the expression of glycoproteins of vesicular stomatitis virus and Sindbis virus in 293T producer cells results in the spontaneous shedding of enveloped particles ([Moore et al., 2006](#), [Mangeot et al., 2011](#)). Thus, we suspect that virus preparations contain a mixture of particles with and without the viral RNA genome. We are uncertain whether only one or both types of particles contain the protein and cellular DNA that are involved in DC stimulation and T cell response. Separation of the various types of particles has been difficult, but with the

improvement and accessibility of single nanoparticle sorting, the answers to these questions are now within our reach.

In addition, we assume that the vector-encoded protein contained in the viral particles is merely encapsulated cytoplasm because we found both OVA and GFP in the particles. However, there may be more specific interactions involved. How DNA is packaged within particles is more of a mystery. HIV infection induces cell death by pyroptosis, a process that leads to DNA fragmentation ([Doitsh et al., 2014](#)). It could be that as cells die, the HIV particles being produced pick up fragmented DNA from the host cell. We also detected human genomic DNA within LV and VLP particles, the formation of which should not involve pyroptosis. The ability of LVs and VLPs to package human genomic DNA may be a result of liposomal transfection reagents, which are cyto- and genotoxic, inducing host DNA damage and increasing cytosolic dsDNA in cells ([Knudsen et al., 2015](#), [Shen, 2014](#)). Thus, the fragmented, cytoplasmic genomic DNA may be available for encapsulation in many cell types via different processes. Further studies are needed to determine the immunologic significance of human genomic DNA delivered by viral particles.

This study began as an investigation of a particular form of technology, DC-targeted LV. As the work has progressed, aspects of viral interaction with host immunity have become evident and that have helped to understand the transduction process but have raised multiple questions about what is delivered by viral vectors. Our findings suggest that cellular DNA may act as a viral ligand to the STING pathway. The development of DNA adjuvants that serve as STING agonists could provide a new therapeutic strategy for inducing CD8<sup>+</sup> T cell responses. Additionally, our finding that lentiviral vectors

package tumor cell DNA from producer cells raises a potential safety concern for viral vector-based gene therapies, which merit further investigation.

## EXPERIMENTAL PROCEDURES

**Statistics, sample size selection, and exclusion criteria.** All experimental group sizes were selected to ensure adequate statistical power despite the variable nature of the studies performed. No animals were excluded from the study. Groups of animals were chosen in consecutive order and were not randomized prior to commencing the study. Animal studies were not performed in a blinded fashion.

**Mice.** C57BL/6J, MyD88<sup>-/-</sup>, TRIF mutant (C57BL/6J-Ticam1<sup>Lps2</sup>), Tmem173<sup>-/-</sup>, and OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J) mice were obtained from The Jackson Laboratory. IPS-1<sup>-/-</sup> mice were provided by G. Cheng (UCLA). MyD88<sup>-/-</sup>/Ticam1<sup>Lps2/Lps2</sup> and MyD88<sup>-/-</sup>/IPS-1<sup>-/-</sup> mice were generated and bred. p50<sup>-/-</sup> mice have been described ([Sha et al., 1995](#)). All mice were maintained on the C57BL/6J background and used according to protocols approved by Institutional Animal Care and Use Committee at Caltech. Experiments were performed with mice 6-12 weeks of age with sex-matched littermates.

**Antibodies and flow cytometry.** Single-cell suspensions were stained with the following antibodies from Biolegend: Pacific blue-anti-mouse CD11b (117321), Pacific blue-anti-mouse CD44 (103020), PE-anti-mouse CD62L (104408), PE-anti-human CD11c (301606), PE/Cy7-conjugated anti-mouse I-Ab (115420), PE/Cy7-anti-mouse CD69 (104512), PerCP-anti-human CD14 (325621), APC-anti-mouse CD11c (11730), APC-anti-human CD86 (305411), APC/Cy7- anti-mouse CD86 (105030), and APC/Cy7-anti-human HLA-DR (307617). For dead cell staining, 1  $\mu\text{g ml}^{-1}$  of propidium iodine was added. APC-conjugated H-2K<sup>b</sup> tetramers bound to the OVA-derived peptide SIINFEKL were obtained from the NIAID Tetramer Facility. Cells were analyzed on a MACSQuant analyzer (Miltenyi), data were analyzed with FlowJo software (TreeStar).

**Isolation and culture of DCs.** Differentiation of mouse BMDCs was achieved by culture for 8 d in media containing granulocyte-macrophage colony-stimulating factor (GM-CSF) (1:25 J558L conditioned medium) as previously described ([Dai et al., 2009](#)). Human moDCs were generated by culture for 8 d of CD14<sup>+</sup> peripheral blood monocytes (UCLA Center for AIDS Research (CFAR) Virology Core Lab) in media containing human GM-CSF and IL-4 (Peprotech). BMDCs and moDCs were cultured in RPMI-1640 medium supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Sigma), 1% (vol/vol) non-essential amino acids (HyClone), 1mM sodium pyruvate (Gibco), 10mM HEPES (Gibco), and 0.05mM 2-mercaptoethanol (Gibco).

**Cell lines.** HEK293T/17 cells (ATCC) and 293T.DCSIGN cells, which were generated as previously described ([Yang et al., 2008](#)), were cultured in DMEM with 10% (vol/vol) FBS. EL4 (C57BL/6J, H-2<sup>b</sup>, thymoma) and E.G7 (EL4 cells stably expressing one copy of chicken OVA cDNA) provided by L. Yang (UCLA) and GXR.CEM human lymphoblastoid CD4<sup>+</sup> T cells provided by B. Walker (Ragon Institute) were cultured in RPMI-1640 medium with 10% (vol/vol) FBS. All media was supplemented with 1% (vol/vol) penicillin and streptomycin (Gibco).

**LV, VLP, and infectious HIV-1.** The LV transfer vectors (FUGW, FOVA) used in this study are the third generation HIV-based LVs. FUGW encodes the GFP and FOVA encodes an invariant chain-OVA fusion construct as previously described ([Hu et al., 2011](#)). The plasmids pMDLg/pRRE encoded *gag* and *pol* and pRSV-Rev encoded *rev*. The envelope plasmids used were p.VSV-G and p.SVGmu ([Yang et al., 2008](#)). Introducing mutations G124A and P127A as previously described ([Zhang and Ghosh, 1994](#)) generated the fusion-defective VSV-G. The pNL4-3 plasmid used to generate

infectious HIV-1 was obtained from the AIDS Reagent Program, Division of AIDS, NIAID, NIH. Virus was prepared by culturing HEK293T/17 cells in 10-cm tissue culture dishes and transfecting with BioT (Bioland Scientific, Paramount CA) according to manufacturer's instructions using a total of 10 µg DNA. For production of LV, we used the LV transfer vector plasmid, which encodes the viral genome (4 µg), and 2 µg each of the packaging plasmids (pMDLg/pRRE, pRSV-Rev), and the envelope plasmid (VSVG, SVGmu, VSVG.fd). LV encoding GFP used the LV transfer vector plasmid FUGW and LV encoding OVA used the LV transfer vector plasmid FOVA. To generate LV encoding GFP and carrying OVA, the plasmids FUGW, pMDLg/pRRE, pRSV-Rev, p.SVGmu, and an expression plasmid encoding the invariant chain-OVA fusion construct (p.OVA) were used. To generate VLPs lacking a viral genome, the LV transfer vector plasmid was omitted. Capsid deficient vectors were generated by omitting the packaging plasmids pMDLg/pRRE and pRSV-Rev. Consistent with previous findings, transfection of 293T producer cells with the LV packaging plasmids encoding *gag*, *pol* and *rev* generated "bald" particles ([Cowan et al., 2002](#)). To generate VLPs carrying GFP or OVA, an expression plasmid encoding GFP (p.GFP) or p.OVA was included during transfections. Puc19 plasmid was transfected into 293T cells as a negative control. To generate an infectious molecular clone of HIV-1, 20 µg of pNL4-3 plasmid was used for transfections. All viral supernatants were harvested at 36, 48, and 60 h post-transfection and filtered through a 0.45-µm filter. The cell-free LV and VLP supernatants were additionally ultracentrifugated (Optima L-80 K preparative ultracentrifuge, Beckman Coulter) at 80,000 *g* for 90 min through a 20% (vol/vol) sucrose cushion. The pellets were then resuspended in an appropriate volume of cold PBS. 293T and 293T.DCSIGN cells were infected with LV and cells analyzed for GFP expression by flow cytometry to determine the transduction titer by the dilution ranges that exhibited a linear response. The concentration of gag was measured by p24 capture ELISA Kit (ImmunoDiagnostics) and

GFP by GFP ELISA Kit (Abcam). The concentration of iOVA was determined using a sandwich ELISA. The 96-well plates were coated with anti-CD74 at  $5 \mu\text{g ml}^{-1}$  (555317; BD Biosciences) and blocked with PBS containing 1% (vol/vol) BSA. The vectors were lysed in 0.5% (vol/vol) Triton X-100 and incubated on coated plates. The amount of captured OVA was determined using anti-chicken OVA at  $5 \mu\text{g ml}^{-1}$  (1221; Abcam). Detection was performed using a horseradish peroxidase-conjugated goat-anti-mouse IgG (Bethyl Lab) at a dilution of 1:10,000. Colorimetric analysis was performed using TMB Peroxidase Substrate System (KPL) and absorbance was read at 450nm.

**DC treatment with vectors.** DCs ( $1-2 \times 10^6$  cells) were centrifuged with LV ( $1-2 \times 10^6$  transduction units; 100–200 ng of p24, GFP, or OVA) or VLP (100–200 ng of p24; 100–200 ng of GFP) at 1,050 g at 30 °C for 90 min. After centrifugation, the supernatant was removed and replaced with fresh medium and cytokines and incubated at 37 °C with 5% of CO<sub>2</sub>. Post-treatment, the supernatant was removed and replaced with fresh medium containing cytokines and incubated at 37 °C with 5% of CO<sub>2</sub>. Cycloheximide (CHX) and chloroquine (CQ) (Sigma) were added to cell cultures 1 h prior to LV treatment and was added back to the fresh medium. Tenofovir (TFV) and efavirenz (EFV) (AIDS Research and Reference Reagent Program, NIAID/NIH) were added to cell cultures 6 h prior to LV treatment and after centrifugation drugs were added to the fresh media.

**Mouse immunization and tumor challenge.** LVs and VLPs were injected subcutaneously into the right flank of mice. Priming immunization contained between 25–50 ng of p24. All vectors were normalized to equivalent amounts of OVA and/or p24 by ELISA. During prime-boost immunization, the vector doses of the prime and boosts were identical. Blood was collected from the immunized mice and PBMCs processed and analyzed for the presence of OVA-specific T cells using a Class I H-2K<sup>b</sup>-SIINFEKL

tetramer and their surface activation markers using flow cytometry. For homologous boosts, mice received the same dose of LV and VLP in the right flank. Unimmunized mice received equal volume injections of PBS. For the tumor protection experiments, mice received  $1-5 \times 10^6$  EL4 or E.G7 cells injected subcutaneously into the opposing flanks of the mice. Tumor size was measured and shown as a product of the two largest perpendicular diameters  $a \times b$  ( $\text{mm}^2$ ). In these experiments, the mice were killed when the tumors reached  $200 \text{ mm}^2$ . In the experiments using reverse transcriptase inhibitors (RTIs) in vivo, tablets containing efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg were crushed, resuspended in PBS containing 1% (vol/vol) DMSO, filtered through a  $0.22 \mu\text{m}$  filter, and stored in aliquots at  $-80 \text{ }^\circ\text{C}$ . RTIs were added to the fresh drinking water of mice at the following approximate concentrations: efavirenz  $10 \text{ mg ml}^{-1}$ , emtricitabine  $3.6 \text{ mg ml}^{-1}$ , tenofovir  $5.4 \text{ mg ml}^{-1}$ . Fresh water containing RTIs was replaced two times a week. Mice receiving no RTIs were given similar volumes of drinking water and replaced accordingly. Mice were initiated on the oral regimen of RTIs one week prior to immunization and continued throughout the duration of the experiment.

**Immunoblot analysis.** Vector preparations were lysed in 1% Triton X-100 in PBS supplemented with HALT protease and phosphatase inhibitor cocktail (Life Technologies) and clarified by centrifugation. Aliquots of the lysate were mixed with non-reduced Laemmli's sample buffer and resolved by 5–15% (wt/vol) SDS-PAGE. After transfer to nitrocellulose, the following antibodies were used: GFP (8334; Santa Cruz), OVA (1221; Abcam), VSVG (v5507; Sigma), and p24 (10R-H120b; Fitzgerald). To determine if proteins were inside the vector particles, samples were pre-treated with proteinase K  $10 \mu\text{g ml}^{-1}$  (Qiagen) and incubated at  $55 \text{ }^\circ\text{C}$  for 1 h, and then the proteinase K was inactivated with PMSF 1mM (Sigma) before samples were lysed.

**In vitro DC stimulation of OT-1 cells.** Mouse BMDCs were spin-infected with VLPs carrying OVA, and washed and resuspended in fresh media and  $1 \mu\text{g ml}^{-1}$  LPS).  $\text{CD8}^+$  T cells were purified using MACS Columns (Miltenyi) from the spleen cells of OT-1 transgenic mice and cultured with the uninfected or VLP-infected BMDCs at a ratio of 1:1. The cells were collected and analyzed for their surface activation markers using flow cytometry 24 h after co-culture. Splenocytes were collected from STING-deficient and wild-type mice and treated with PMA ( $50 \text{ ng ml}^{-1}$ ) and Ionomycin ( $500 \text{ ng ml}^{-1}$ ) for 24h, 48h, and 72 h. Cells were then collected and analyzed for their surface activation markers using flow cytometry.

**Fluorescent imaging.** Cells were washed once with cold PBS and then fixed using 4% (vol/vol) cold paraformaldehyde in PBS (10 min at  $22 \text{ }^\circ\text{C}$ ) followed by washing 4 times with cold PBS. Images were collected using a fluorescence microscope (Axiovert 200m; Zeiss) equipped with three filter wheels (Lambda 10-3; Sutter Instruments), and a cooled CCD camera (Evolution/Qimaging; Media Cybernetics). Images were collected using Image-ProPlus 5.1 software (Media Cybernetics). All data within each experiment were collected at identical imaging settings; relevant sets of images were adjusted only for brightness/contrast.

**Liposomes.** Multilamellar liposomes were prepared based on the conventional dehydration-rehydration method as previously described ([Liu et al., 2014](#)). DOPC, DOPG and MPB-PE (NOF Corporation) were combined in chloroform, at a molar lipid ratio of DOPC:DOPG:MPB = 4:1:5, and the organic solvent in the lipid mixture was evaporated under argon gas. The lipid mixture was further dried under vacuum overnight to form dried thin lipid films. The resultant dried film containing  $1.12 \mu\text{g}$  of lipids was

hydrated in 10 mM Bis-Tris propane at pH 7.0 with GFP (STA-201; Cell Biolabs) at a concentration of  $125 \text{ ng ml}^{-1}$  in a total volume of 300  $\mu\text{l}$ . Polyhistidine tagged VSV-G was expressed and purified from a suspension 293-E cells after a 48-h transfection using Ni-NTA column purification. Purified VSV-G protein ( $200 \text{ } \mu\text{g ml}^{-1}$ ) was added to the lipid hydration mixture before sonication. Alternatively, 5 ml of VSV-G enveloped VLPs, collected from the medium of 293T cell transfected with p.VSVG and purified and concentrated as described above, was added to the lipid hydration mixture, as previously described ([Abe et al., 1998](#)), and DNA was not detectable by PCR in the liposomes made by this method. To add DNA into the liposomes,  $30 \text{ } \mu\text{g ml}^{-1}$  of genomic DNA extracted from 293T cells or plasmid DNA was added to the lipid hydration mixture. Lipid film and hydration mixture were vigorously vortexed every 10 min for 1 h, and then applied with 4 cycles of 15 s sonication (Misonix Microson XL2000) on ice in 1 min intervals for each cycle. To induce divalent-triggered vesicle fusion,  $\text{MgCl}_2$  was added at a final concentration of 10 mM. The resulting multilamellar vesicles were further cross-linked by addition of Dithiothreitol (Sigma) at a final concentration of 1.5 mM for 1 h at  $37 \text{ }^\circ\text{C}$ . The resulting vesicles were collected by centrifugation at  $14,000 \text{ g}$  for 4 min and then washed twice with PBS.

**DNA analysis.** Virus and VLP samples were inactivated/lysed by heating to  $95 \text{ }^\circ\text{C}$  for 15 min. To determine whether DNA was carried within the particles, virus and VLP samples were pre-treated with DNase I (Sigma) at a final concentration of  $0.1 \text{ mg ml}^{-1}$  at room temperature for 10 min, and then the DNase I was inactivated with EDTA  $0.625 \text{ mM}$  at  $70 \text{ }^\circ\text{C}$  for 10 min, before inactivation/lysis. To show that DNase I degradation was complete, DNase I was not inactivated by EDTA prior to lysis. PCR amplifications from samples were carried out in 0.2-mL thin-walled reaction vessels in the Eppendorf Mastercycler proS. The manufacturer-supplied reaction buffer of REExtract-N-Amp

PCR ReadyMix (Sigma) was used at concentration of 1× in 25 µl reaction mixtures per manufacturer instructions to obtain readily visible PCR products after 35–40 amplification cycles (30 s at 95 °C, 30 s at 50 °C and 1 min at 72 °C). The following primer sequences were used for identification of DNA: VSV-G 5'-TGAAGTGCCTTTTGTACTTAGCCTTTTATTC-3' and 5'-ACCAGCGGAAATCACAAAGTAGTGACC-3'; amp<sup>R</sup> 5'-AATCAGTGAGGCACCTATCTCAGCG-3' and 5'-AAGCCATACCAAACGACGAGCG-3'; AluYd6 (human), 5' GAGATCGAGACCACGGTGAAA-3' and 5'-TTTGAGACGGAGTCTCGTT-3' as previously described ([Walker et al., 2003](#)); ACTB (human), 5'-CATGTACGTTGCTATCCAGGC-3', and 5'-ATTACCCACTCCCGACCCG (Primerbank ID 4501885a1). The amplification products were electrophoresed on 2% (wt/vol) agarose gel with subsequent ethidium bromide staining.

**HIV passaging.** Anonymous human PBMCs were provided by the UCLA Center for AIDS Research (CFAR) Virology Core Lab (peripheral blood). PBMCs were cultured in 5 µg ml<sup>-1</sup> PHA (Sigma) in the presence of 5 ng ml<sup>-1</sup> IL-2 (Peprotech) cells at 1 × 10<sup>6</sup> cells ml<sup>-1</sup> and infected with 50 ng p24 of NL4-3 virus supernatant and incubated at 37 °C for 1 d. Infected cells were washed and and incubated again at 37 °C for 2 d. Uninfected cells were concurrently treated in an identical manner. Cell-free supernatant was collected and filtered through a 0.22 µm filter. Aliquots of cell-free supernatants were stored at –80 °C. All work was approved by the California Institute of Technology Institutional Biosafety Committee and Institutional Review Board exempt.

**Statistical Analyses.** GraphPad Prism 6.0 software was used for data analysis. Statistical significance was determined by unpaired, two-sided Student's *t*-tests for two

groups or one-way ANOVA (with post-hoc Tukeys' multiple comparison test) for three or more groups.

## FIGURE LEGENDS

### **Figure 1. Lentivector (LV) pseudotransduction delivers proteins and stimulates dendritic cells (DCs).**

(A) Mouse bone marrow-derived DCs (BMDCs), human monocyte-derived DCs (moDCs), and 293T cells were incubated with tenofovir (TFV) 40  $\mu$ M, efavirenz (EFV) 80  $\mu$ M, or no drug (ND) 6 h prior to treatment with VSV-G-pseudotyped LV expressing GFP (LV-GFP(V)), and then analyzed 24 h later for GFP expression by flow cytometry.

(B) GFP mean fluorescent intensity (MFI) of DCs as treated in A.

(C) Mouse BMDCs were incubated with or without cycloheximide (CHX) for 1 h prior to treatment with LV-GFP(V) and GFP MFI measured by flow cytometry over 4 h. Results are presented relative to those of BMDCs receiving no LV with or without CHX.

(D) Western blot analysis of GFP of vector lysates from LV-GFP(V) and LV expressing ovalbumin (OVA) pseudotyped with VSV-G (LV-OVA(V)) and 40ng of purified GFP protein. Analysis of VSV-G was used as a loading control for the vectors.

(E,F) mouse BMDCs (E) and human moDCs (F) were treated as in A and analyzed for activation by measuring the MHC II molecule I-Ab and/or CD86 by flow cytometry. n.s.=not significant with  $P > 0.05$ ; \*\*\* $P < 0.001$  (unpaired Student's t-test (B,D,F)). Data are representative of at least two independent experiments (A,B,D-F) or three independent experiments (C). Results are shown as mean  $\pm$  s.e.m of technical replicates (B,C,E). See also Figure S1.

### **Figure 2. LV DNA, genome, and capsid are not required for DC maturation and CD8<sup>+</sup> T cell priming.**

(A,B) Schematic diagram of VLPs and corresponding Western blot analysis for GFP, VSV-G, and p24 on LV and VLP lysates.

(C,D,E) Mouse BMDCs and human moDCs were treated with VSV-G or SVGmu-pseudotyped LVs and VLPs and then analyzed at 24 h for GFP, CD86, and I-Ab or HLA-DR expression by flow cytometry.

(F-I) Wild-type mice received homologous prime-boost vaccination of SVGmu-pseudotyped LV expressing OVA (LV-OVA) with or without RTI or SVGmu-pseudotyped VLP carrying OVA (VLP-OVA). (F) Flow cytometry analyzed the frequency of OVA-specific tetramer (H-2K<sup>b</sup>-SIINFEKL)<sup>+</sup> CD8<sup>+</sup> T cells from the blood at 7 and 10 d post-primary immunization. Numbers adjacent to outlined areas indicate percent of tetramer<sup>+</sup> cells among the total CD8<sup>+</sup> T cells. (G) Tetramer<sup>+</sup> CD8<sup>+</sup> T cells from the blood of immunized and unimmunized mice were measured by flow cytometry (black arrow, boost). (H) Flow cytometry analyzed CD62L and CD44 expression of tetramer<sup>+</sup> CD8<sup>+</sup> T cells from immunized mice compared or naïve CD8<sup>+</sup> T cells from unimmunized mice at 41 d. (I) Seven wk post-boost, mice were injected with OVA-expressing and control tumor cells on opposing legs and tumor sizes measured.

(J,K) Wild-type mice were homologously prime-boosted with LV-OVA, VLP-OVA, or VLP without capsid carrying OVA (VLP-OVA $\Delta$ gag). (J) Tetramer<sup>+</sup> CD8<sup>+</sup> T cells were measured from the blood. (K) Mice were injected with tumor cells as in I.

(L) Wild-type mice were injected with LV-OVA, LV encoding OVA carrying GFP (LV-GFP<sup>gene</sup>-OVA<sup>protein</sup>), or VLP-OVA. Tetramer<sup>+</sup> CD8<sup>+</sup> T cells were measured from the blood. n.s.=not significant with  $P > 0.05$ ; \* $P < 0.05$ ; \*\*\* $P < 0.001$  (unpaired Student's t-test (C,D)). Data are representative of two independent experiments (B-E; mean  $\pm$  s.e.m. of technical replicates in C-E), one experiment (G-I; mean  $\pm$  s.e.m. of  $n = 8$  mice per group in E,G,H-J), or representative of two independent experiments (J-L; mean  $\pm$  s.e.m. of  $n = 8$  mice per group). See also Figure S2.

**Figure 3. LV activation of DCs and subsequent CD8<sup>+</sup> T cell priming is dependent on STING, but not MyD88, TRIF, or IPS-1.**

(A) BMDCs from mice deficient in MyD88, TRIF, and IPS-1 were treated with LV-GFP(V) or LV-GFP(S) and analyzed at 24 h for expression of CD86 and I-Ab by flow cytometry.

(B-D) Mice deficient in MyD88, TRIF, IPS-1, or STING were immunized with LV-OVA.

(B) Flow cytometry analyzed the frequency of OVA-specific tetramer<sup>+</sup> CD8<sup>+</sup> T cells from the blood at 10 d post-immunization. Numbers adjacent to outlined areas indicate percent of tetramer<sup>+</sup> cells among the total CD8<sup>+</sup> T cells. (C) Tetramer<sup>+</sup> CD8<sup>+</sup> T cells from the blood of immunized mutant and wild-type mice or unimmunized wild-type mice ( $n = 6$  mice per group). Values between the groups of immunized mutant and wild-type mice at 10 d showed no statistical significance. (D,E) CD62L and CD44 expression of tetramer<sup>+</sup> CD8<sup>+</sup> T cells from immunized wild-type and mutant mice compared to naïve CD8<sup>+</sup> T cells from unimmunized wild-type mice at 10 d ( $n = 6$  mice per group).

(F) Tetramer<sup>+</sup> CD8<sup>+</sup> T cells from the blood of immunized STING-deficient and wild-type mice ( $n = 5$  mice per group).

(G) CD62L<sup>lo</sup> and CD44<sup>+</sup> tetramer<sup>+</sup> CD8<sup>+</sup> T cells from STING-deficient and wild-type mice at 10 d ( $n = 5$  mice per group).

Each symbol (C,E) represents the mean; error bars indicate s.e.m. Each symbol (E,G) represents an individual mouse; small horizontal lines indicate the mean. n.s., not significant,  $P > 0.05$  (one way-ANOVA (A,C,E));  $*P < 0.05$  (unpaired Student's t-test (f)). Data are from one experiment representative of three independent experiments (A; mean and s.e.m.), two independent experiment (B-E), or pooled from two experiments (F,G). See also Figures S1, S3, and S4.

**Figure 4. Viral-like particles (VLPs) activate DCs and antigen-specific CD8<sup>+</sup> T cells via the STING pathway.**

(A) BMDCs from STING-deficient and wild-type mice were treated with VLP carrying GFP pseudotyped with VSV-G (VLP-GFP(V)) or SVGmu (VLP-GFP(S)) and analyzed at 24 h for CD86 and I-Ab expression by flow cytometry.

(B) STING-deficient and wild-type BMDCs were treated with VLP-OVA pseudotyped with VSV-G (VLP-OVA(V)) or SVGmu (VLP-OVA(S)) and then cocultured with OT-1 CD8<sup>+</sup> T cells for 24 h. The CD8<sup>+</sup> T cells were analyzed for expression of activation markers CD69 and CD25 by flow cytometry.

(C-E) STING-deficient and wild-type mice were homologously prime-boosted with SVGmu-pseudotyped VLP-OVA. (C) Flow cytometry analyzed the frequency of OVA-specific tetramer<sup>+</sup> CD8<sup>+</sup> T cells from the blood at 7 d post-boost. Numbers adjacent to outlined areas indicate percent of tetramer<sup>+</sup> cells among the total CD8<sup>+</sup> T cells. (D) Tetramer<sup>+</sup> CD8<sup>+</sup> T cells from the blood of immunized STING-deficient and wild-type mice and unimmunized wild-type mice measured (black arrow, boost); (*n* = 8 mice per group). (E) CD62L<sup>lo</sup> and CD44<sup>+</sup> tetramer<sup>+</sup> CD8<sup>+</sup> T cells from STING-deficient and wild-type mice at 7 d post-boost (*n* = 8 mice per group).

Each symbol (D) represents the mean; error bars indicate s.e.m. Each symbol (E) represents an individual mouse; small horizontal lines indicate the mean. n.s., not significant, *P* > 0.05; \**P* < 0.05; \*\**P* < 0.005; \*\*\**P* < 0.001 (unpaired Student's t-test (A,B,E)). Data are from one experiment representative of three independent experiments (A; error bars indicate s.e.m.), two independent experiments (B; error bars indicate s.e.m.), or pooled from two independent experiments (C-E).

### **Figure 5. Viral fusion is required for DC activation.**

(A) Mouse BMDCs were incubated with chloroquine (CQ) at 25 μM, 75 μM, 100 μM (wedges) or no drug (ND) 1 h prior to treatment with LV or VLPs, and analyzed at 24 h for CD86 and I-Ab expression by flow cytometry.

(B) Fluorescence microscopy of mouse BMDCs treated with fusion-competent VLP-GFP(V) with or without CQ or fusion-defective VLP-GFP(V.FD). 400× magnification scale bar = 10 μm.

(C) Mouse BMDCs were infected with fusion-competent or fusion-defective LVs or VLPs carrying GFP and analyzed for CD86 and I-Ab expression.

(D,E) BMDCs from wild-type and STING-deficient mice were treated with naked (Lipo) or VSV-G enveloped multilamellar liposomes (Lipo(V)) carrying GFP and analyzed at 24 h for CD86 and I-Ab expression.

n.s., not significant,  $P > 0.05$ ;  $***P < 0.001$  (unpaired Student's t-test (C,D,E)). Data are from one experiment representative of three independent experiments (A,C,D; error bars indicate s.e.m.) or two independent experiments (B,E; error bars indicate s.e.m.).

**Figure 6. LV particles and VLPs contain human genomic DNA recognized by the host STING pathway.**

(A) Amplicons of human  $\beta$ -actin (*ACTB*) and the ampicillin resistance gene (*amp*) detected in the LV and VLP preparations by PCR. The cell-free supernatant collected from 293T cells transiently transfected with mock plasmid puc19 was used as a negative control.

(B) Amplicons of human Alu element (*Alu*) and VSV-G (*VSV-Gp4*) were amplified from VLP preparations or genomic DNA (lane 1). VLP preparations or genomic DNA was treated with DNase I leading to DNA degradation (lane 2). If the DNase I was inactivated with EDTA before lysis, then DNA continued to be detected (lane 3). DNase I was inactivated with EDTA, and then VLP lysate added to show DNase I was effectively inactivated (lane 4).

(C) Amplicons of human DNA from 293T cellular genomic DNA treated in the same conditions as in B.

(D) PCR analysis for amplicons of human *ACTB* and *Alu* and plasmid from cell-free supernatant collected from 293T cells transiently transfected with the plasmid p.NL4-3 encoding infectious HIV-1 or 293T genomic DNA.

(E) NL4-3 HIV-1 was passaged in primary PBMCs and the cell-free supernatant was collected and analyzed for human *ACTB*. As a negative control, cell-free supernatant was collected from uninfected PBMCs.

(F) Amplicons of human *ACTB* and *Alu* were detected in cell-free supernatant containing NL4-3 HIV-1 passaged in primary PBMCs (lane 1). HIV-1 supernatant was treated with DNase I (lane 2), and then DNase I was inactivated by EDTA (lane 3) before lysis. DNase I was inactivated with EDTA and HIV lysate added to show DNase I was effectively inactivated (lane 4).

(G,H) BMDCs from STING-deficient or wild-type mice were treated with naked (Lipo) or VSV-G-enveloped multilamellar liposomes carrying plasmid DNA (Lipo-plasmid(V)), genomic DNA extracted from 293T cells (Lipo-gDNA(V)), or nothing (Lipo(V)). Cells were analyzed 24 h post-treatment for CD86 and I-Ab expression by flow cytometry.

n.s., not significant,  $P > 0.05$ ;  $*P < 0.05$ ;  $***P < 0.001$  (unpaired Student's t-test (G,H)).

Data are from one experiment representative of three independent experiments (A-F) or two independent experiments (G,H; error bars indicate s.e.m.). See also Figure S5.

## REFERENCES

- ABE, A., MIYANOHARA, A. & FRIEDMANN, T. 1998. Enhanced gene transfer with fusogenic liposomes containing vesicular stomatitis virus G glycoprotein. *J Virol*, 72, 6159-63.
- ARCE, F., ROWE, H. M., CHAIN, B., LOPES, L. & COLLINS, M. K. 2009. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. *Mol Ther*, 17, 1643-50.
- BEIGNON, A. S., MCKENNA, K., SKOBERNE, M., MANCHES, O., DASILVA, I., KAVANAGH, D. G., LARSSON, M., GORELICK, R. J., LIFSON, J. D. & BHARDWAJ, N. 2005. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. *J Clin Invest*, 115, 3265-75.
- BERG, R. K., MELCHJORSEN, J., RINTAHAKA, J., DIGET, E., SOBY, S., HORAN, K. A., GORELICK, R. J., MATIKAINEN, S., LARSEN, C. S., OSTERGAARD, L., PALUDAN, S. R. & MOGENSEN, T. H. 2012. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. *PLoS One*, 7, e29291.
- BERNIER, R. & TREMBLAY, M. 1995. Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1. *J Virol*, 69, 291-300.
- BONIFAZ, L., BONNYAY, D., MAHNKE, K., RIVERA, M., NUSSENZWEIG, M. C. & STEINMAN, R. M. 2002. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. *J Exp Med*, 196, 1627-38.
- BRECKPOT, K., DULLAERS, M., BONEHILL, A., VAN MEIRVENNE, S., HEIRMAN, C., DE GREEF, C., VAN DER BRUGGEN, P. & THIELEMANS, K. 2003. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. *J Gene Med*, 5, 654-67.
- BRECKPOT, K., EMEAGI, P., DULLAERS, M., MICHIELS, A., HEIRMAN, C. & THIELEMANS, K. 2007. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. *Hum Gene Ther*, 18, 536-46.
- BRECKPOT, K., ESCORS, D., ARCE, F., LOPES, L., KARWACZ, K., VAN LINT, S., KEAERTS, M. & COLLINS, M. 2010. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. *J Virol*, 84, 5627-36.
- CHINNASAMY, N., CHINNASAMY, D., TOSO, J. F., LAPOINTE, R., CANDOTTI, F., MORGAN, R. A. & HWU, P. 2000. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. *Hum Gene Ther*, 11, 1901-9.
- COWAN, S., HATZIOANNOU, T., CUNNINGHAM, T., MUESING, M. A., GOTTLINGER, H. G. & BIENIASZ, P. D. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. *Proc Natl Acad Sci U S A*, 99, 11914-9.
- DAI, B., YANG, L., YANG, H., HU, B., BALTIMORE, D. & WANG, P. 2009. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. *Proc Natl Acad Sci U S A*, 106, 20382-7.
- DILLE, B. J. & JOHNSON, T. C. 1982. Inhibition of vesicular stomatitis virus glycoprotein expression by chloroquine. *J Gen Virol*, 62 (Pt 1), 91-103.
- DOITSH, G., GALLOWAY, N. L., GENG, X., YANG, Z., MONROE, K. M., ZEPEDA, O., HUNT, P. W., HATANO, H., SOWINSKI, S., MUNOZ-ARIAS, I. & GREENE, W.

- C. 2014. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. *Nature*, 505, 509-14.
- DULLAERS, M., VAN MEIRVENNE, S., HEIRMAN, C., STRAETMAN, L., BONEHILL, A., AERTS, J. L., THIELEMANS, K. & BRECKPOT, K. 2006. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. *Gene Ther*, 13, 630-40.
- DYALL, J., LATOUCHE, J. B., SCHNELL, S. & SADELAIN, M. 2001. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. *Blood*, 97, 114-21.
- ELOUAHABI, A. & RUYSSCHAERT, J. M. 2005. Formation and intracellular trafficking of lipoplexes and polyplexes. *Mol Ther*, 11, 336-47.
- ESSLINGER, C., CHAPATTE, L., FINKE, D., MICONNET, I., GUILLAUME, P., LEVY, F. & MACDONALD, H. R. 2003. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. *J Clin Invest*, 111, 1673-81.
- FLORKIEWICZ, R. Z. & ROSE, J. K. 1984. A cell line expressing vesicular stomatitis virus glycoprotein fuses at low pH. *Science*, 225, 721-3.
- GALLA, M., WILL, E., KRAUNUS, J., CHEN, L. & BAUM, C. 2004. Retroviral pseudotransduction for targeted cell manipulation. *Mol Cell*, 16, 309-15.
- GAO, D., WU, J., WU, Y. T., DU, F., AROH, C., YAN, N., SUN, L. & CHEN, Z. J. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. *Science*, 341, 903-6.
- GRANELLI-PIPERNO, A., ZHONG, L., HASLETT, P., JACOBSON, J. & STEINMAN, R. M. 2000. Dendritic cells, infected with vesicular stomatitis virus-pseudotyped HIV-1, present viral antigens to CD4+ and CD8+ T cells from HIV-1-infected individuals. *J Immunol*, 165, 6620-6.
- HAAS, D. L., CASE, S. S., CROOKS, G. M. & KOHN, D. B. 2000. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. *Mol Ther*, 2, 71-80.
- HE, Y. & FALO, L. D. 2007. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. *Current Opinion in Molecular Therapeutics*, 9, 439-446.
- HE, Y., ZHANG, J., MI, Z., ROBBINS, P. & FALO, L. D., JR. 2005. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. *J Immunol*, 174, 3808-17.
- HOLM, C. K., JENSEN, S. B., JAKOBSEN, M. R., CHESHENKO, N., HORAN, K. A., MOELLER, H. B., GONZALEZ-DOSAL, R., RASMUSSEN, S. B., CHRISTENSEN, M. H., YAROVINSKY, T. O., RIXON, F. J., HEROLD, B. C., FITZGERALD, K. A. & PALUDAN, S. R. 2012. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. *Nat Immunol*, 13, 737-43.
- HU, B., TAI, A. & WANG, P. 2011. Immunization delivered by lentiviral vectors for cancer and infectious diseases. *Immunol Rev*, 239, 45-61.
- ISHIKAWA, H., MA, Z. & BARBER, G. N. 2009. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature*, 461, 788-92.
- JAKOBSEN, M. R., BAK, R. O., ANDERSEN, A., BERG, R. K., JENSEN, S. B., TENGCHUAN, J., LAUSTSEN, A., HANSEN, K., OSTERGAARD, L., FITZGERALD, K. A., XIAO, T. S., MIKKELSEN, J. G., MOGENSEN, T. H. & PALUDAN, S. R. 2013. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. *Proc Natl Acad Sci U S A*, 110, E4571-80.
- KNUDSEN, K. B., NORTHEVED, H., KUMAR, P. E., PERMIN, A., GJETTING, T., ANDRESEN, T. L., LARSEN, S., WEGENER, K. M., LYKKESFELDT, J., JANTZEN, K., LOFT, S., MOLLER, P. & ROURSGAARD, M. 2015. In vivo toxicity of cationic micelles and liposomes. *Nanomedicine*, 11, 467-77.

- LIU, Y., FANG, J., JOO, K. I., WONG, M. K. & WANG, P. 2014. Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. *PLoS One*, 9, e110611.
- MANEL, N., HOGSTAD, B., WANG, Y., LEVY, D. E., UNUTMAZ, D. & LITTMAN, D. R. 2010. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. *Nature*, 467, 214-7.
- MANGEOT, P. E., DOLLET, S., GIRARD, M., CIANCIA, C., JOLY, S., PESCHANSKI, M. & LOTTEAU, V. 2011. Protein transfer into human cells by VSV-G-induced nanovesicles. *Mol Ther*, 19, 1656-66.
- METHAROM, P., ELLEM, K. A., SCHMIDT, C. & WEI, M. Q. 2001. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. *Hum Gene Ther*, 12, 2203-13.
- MOORE, P. L., CROOKS, E. T., PORTER, L., ZHU, P., CAYANAN, C. S., GRISE, H., CORCORAN, P., ZWICK, M. B., FRANTI, M., MORRIS, L., ROUX, K. H., BURTON, D. R. & BINLEY, J. M. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. *J Virol*, 80, 2515-28.
- NASH, K. L. & LEVER, A. M. 2004. Green fluorescent protein: green cells do not always indicate gene expression. *Gene Ther*, 11, 882-3.
- ODEGARD, J. M., KELLEY-CLARKE, B., TAREEN, S. U., CAMPBELL, D. J., FLYNN, P. A., NICOLAI, C. J., SLOUGH, M. M., VIN, C. D., MCGOWAN, P. J., NELSON, L. T., TER MEULEN, J., DUBENSKY, T. W., JR. & ROBBINS, S. H. 2015. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy. *J Immunother*, 38, 41-53.
- PICHLMAIR, A., DIEBOLD, S. S., GSCHMEISSNER, S., TAKEUCHI, Y., IKEDA, Y., COLLINS, M. K. & REIS E SOUSA, C. 2007. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. *J Virol*, 81, 539-47.
- ROUAS, R., UCH, R., CLEUTER, Y., JORDIER, F., BAGNIS, C., MANNONI, P., LEWALLE, P., MARTIAT, P. & VAN DEN BROEKE, A. 2002. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. *Cancer Gene Ther*, 9, 715-24.
- SCHROERS, R., SINHA, I., SEGALL, H., SCHMIDT-WOLF, I. G., ROONEY, C. M., BRENNER, M. K., SUTTON, R. E. & CHEN, S. Y. 2000. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. *Mol Ther*, 1, 171-9.
- SHA, W. C., LIOU, H. C., TUOMANEN, E. I. & BALTIMORE, D. 1995. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. *Cell*, 80, 321-30.
- SHEN, Y. J., LE BERT, N., KOO, C.X., HO, S.S., ISHII, K.J., RAULET, D.H., GASSER, S. 2014. Tumor cells express genome-derived DNA in the cytosol. *Cancer Res* 74, 3168.
- SKELTON, D., SATAKE, N. & KOHN, D. B. 2001. The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. *Gene Ther*, 8, 1813-4.
- SMIT, J. M., BITTMAN, R. & WILSCHUT, J. 1999. Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes. *J Virol*, 73, 8476-84.

- SOMAIHAH, N., BLOCK, M.S., KIM, J.W., SHAPIRO, G., HWU, P., EDER, J.P., JONES, R.L., GNJATIC, S., LU, H., HSU, F.J., POLLACK, S. 2015. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. *Journal of Clinical Oncology*, 33, 3021.
- SUN, L., WU, J., DU, F., CHEN, X. & CHEN, Z. J. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science*, 339, 786-91.
- WALKER, J. A., KILROY, G. E., XING, J., SHEWALE, J., SINHA, S. K. & BATZER, M. A. 2003. Human DNA quantitation using Alu element-based polymerase chain reaction. *Anal Biochem*, 315, 122-8.
- YANG, L., YANG, H., RIDEOUT, K., CHO, T., JOO, K. I., ZIEGLER, L., ELLIOT, A., WALLS, A., YU, D., BALTIMORE, D. & WANG, P. 2008. Engineered lentivector targeting of dendritic cells for in vivo immunization. *Nat Biotechnol*, 26, 326-34.
- ZHANG, L. & GHOSH, H. P. 1994. Characterization of the putative fusogenic domain in vesicular stomatitis virus glycoprotein G. *J Virol*, 68, 2186-93.
- ZHU, W., LI, J., TANG, L., WANG, H., LI, J., FU, J. & LIANG, G. 2011. Glycoprotein is enough for sindbis virus-derived DNA vector to express heterogenous genes. *Virology*, 434, 344.

## **SUPPLEMENTAL FIGURE LEGENDS**

### **Figure S1. LVs pseudotransduce and activate mouse BMDCs, related to Figures 1 and 3.**

Mouse BMDCs were treated with LV-GFP(V), LV-GFP(S), LPS, or no vector (NV) and analyzed for expression of GFP, CD86, and I-Ab by flow cytometry.

(A) Numbers adjacent to outlined areas are the GFP MFI values of the CD11c+CD11b+ cells immediate post-LV treatment.

(B) Numbers adjacent to outlined areas are the percent activated CD11c+CD11b+ cells.

(C, D) Time course of the expression of GFP, CD86+ and I-Ab+ BMDCs over 48 h. Each symbol represents the mean; error bars indicate s.e.m. Data are from (A) one experiment representative of five independent experiments or from two independent experiments (B-D). See also Figures 1 and 2.

### **Figure S2. LVs and VLPs carry heterologous proteins, related to Figure 2.**

(A) Western blot analysis of GFP and VSV-G from the viral lysates of LV-GFP(V) and LV expressing ovalbumin (OVA) pseudotyped with SVGmu (LV-OVA(S)).

(B) Western blot analysis for GFP or OVA from the viral lysate of VSVG or SVGmu-pseudotyped VLPs carrying GFP or OVA.

(C) Western blot analysis of OVA in the lysate of SVGmu-pseudotyped VLP carrying OVA. VLP carrying OVA was not treated with proteinase K (PK) or PMSF (lane 1). VLP was pre-treated with PK, and then the PK was inactivated with PMSF before lysis (lane 2). To verify PK degradation was effective, PK was not inactivated before VLP lysis (lane 3). See also Figure 1.

### **Figure S3. MyD88<sup>-/-</sup>/TRIFLps2/Lps2 or MyD88<sup>-/-</sup>/IPS-1<sup>-/-</sup> BMDCs are fully activated by LVs, related to Figure 3.**

(A,B) BMDCs from mice doubly deficient in MyD88 and TRIF (A) or MyD88 and IPS-1 (B) were treated with LV-GFP(V) or LV-GFP(S) and analyzed 24 h post-treatment for the percentage of CD86 and I-Ab-positive cells by flow cytometry. n.s., not significant,  $P > 0.05$  (unpaired Student's t-test). Data from three independent experiments (mean and s.e.m.). See also Figure 3.

**Figure S4. Normal T cell subsets in STING-deficient mice under non-stimulatory conditions, related to Figure 3.**

(A, B) Splenocytes from STING-deficient or wild-type mice were analyzed by flow cytometry using anti-CD4 and anti-CD8 under non-stimulated conditions.


(C) Wild-type and STING-deficient splenocytes were treated with PMA (50ng/ml) and ionomycin (500ng/ml) and cells were analyzed at 24 h, 48 h, and 72 h post-treatment. Surface expression of CD69 and CD25 of the gated CD8<sup>+</sup> T cells was measured by flow cytometry. n.s., not significant,  $P > 0.05$  (unpaired Student's t-test). Data from two independent experiment (mean and s.e.m) (A-C). See also Figure 3.

**Figure S5. LV particles and VLPs contain human genomic DNA, related to Figure 6.**


(A,B) Amplicons of VSV-G (VSIVgp4) and human Alu repeat element (Alu) in the LV and VLP preparations by PCR. See also Figure 5.

## FIGURES


### A




### B




### C




### D




### E




### F




**Figure 1. Lentivector (LV) pseudotransduction delivers proteins and stimulates dendritic cells (DCs).**




**Figure 2. LV DNA, genome, and capsid are not required for DC maturation and CD8<sup>+</sup> T cell priming.**



**Figure 3. LV activation of DCs and subsequent CD8<sup>+</sup> T cell priming is dependent on STING, but not MyD88, TRIF, or IPS-1.**



**Figure 4. Viral-like particles (VLPs) activate DCs and antigen-specific CD8<sup>+</sup> T cells via the STING pathway.**



**Figure 5. Viral fusion is required for DC activation.**








Figure 6. LV particles and VLPs contain human genomic DNA recognized by the host STING pathway.






**Figure S1. LVs pseudotransduce and activate mouse BMDCs, related to Figures 1 and 3.**



**Figure S2. LVs and VLPs carry heterologous proteins, related to Figure 2.**

**A****B**

**Figure S3. MyD88<sup>-/-</sup>TRIFLps2/Lps2 or MyD88<sup>-/-</sup>IPS-1<sup>-/-</sup> BMDCs are fully activated by LVs, related to Figure 3.**

**A****B****C**

**Figure S4. Normal T cell subsets in STING-deficient mice under non-stimulatory conditions, related to Figure 3.**



**Figure S5. LV particles and VLPs contain human genomic DNA, related to Figure 6.**

## Chapter 3

### **Chapter 3: Dendritic cell-to-T cell transmission of HIV is a drug-insensitive mode of infection**

Published as: Jocelyn T. Kim, Emery Chang, Alex Sigal, David Baltimore (2015).

Dendritic cell-to-T cell transmission of HIV is a drug-insensitive mode of infection. *In preparation.*

## **ABSTRACT**

Cell-to-cell transmission of HIV-1 allows for a high amount of concentrated virus to be directed to uninfected target T cells, which overwhelms the capacity of anti-retroviral drugs. During dendritic cell (DC)-to-T cell transmission, uninfected DCs can concentrate infectious virions and transmit them to T cell targets via cellular contacts. Here, we report DCs amplify the efficiency of T cell infection, which results in anti-retroviral drug insensitivity compared to T cell infection in the absence of DCs. The DC-mediated amplification and drug-insensitivity of T cell infection are both entirely dependent on physical cellular interactions. Further, we find the input of virus is important to the drug insensitivity of DC-to-T cell infection, but not DC-free T cell infection. DC-to-T cell transmission of HIV may have important implications for viral persistence *in vivo*.

## INTRODUCTION

Cell-to-cell transmission of HIV is a robust mode of infection, whereby multiple virions infect a target cell (Sigal et al., 2011). During this process, a synapse forms between the infected donor and uninfected target CD4<sup>+</sup> T cells (Sattentau, 2011, Jolly et al., 2011, Sattentau, 2008, McDonald et al., 2003). This close physical proximity enables a high number of virions to be transmitted from the infected donor cell to the uninfected target cell, resulting in a reduced sensitivity to anti-retroviral drugs (Sigal et al., 2011, Sigal and Baltimore, 2012). Cell-to-cell transmission of HIV via a synapse can also occur between DCs and CD4<sup>+</sup> T cells (McDonald et al., 2003, Felts et al., 2010). Infection of the donor DC is not required because DCs can capture infectious virions and transmit them to uninfected target T cells via *trans* infection (Wu and KewalRamani, 2006, Cameron et al., 1992, Dong et al., 2007). It is unclear if DC-to-T cell transmission of HIV is a robust and drug-insensitive mode of infection.

In this study we found that human monocyte-derived DCs amplify HIV infection of autologous T cells in co-culture. This mode of transmission is relatively resistant to reverse transcriptase inhibitors compared to T cell infection in the absence of DCs. Further, it is dependent on physical contact between DCs and T cells. The drug insensitivity of DC-to-T cell infection is dependent on the virus input.

## RESULTS

### DCs amplify T cell infection

To determine the effect of DCs on HIV infection of T cells, we infected PBMCs with NL4-3 in the presence or absence of autologous human monocyte-derived DCs. DCs were matured with LPS prior to co-culture with T cells (**Supplementary Fig. 1**). Previous work indicates that LPS-matured DCs capture significantly more HIV-1 than immature

DCs (Dong et al., 2007, Izquierdo-Useros et al., 2014). To measure T cell infection, cells were analyzed for CD3 surface expression and intracellular p24 by flow cytometry. We found that T cell infection was on average 4-fold higher in DC-T cell coculture compared to DC-free culture across multiple donors (**Fig. 1, Supplementary Fig. 2**). As previously described, LPS-matured DCs showed little evidence of infection by p24 staining (Granelli-Piperno et al., 1999). The ability of DCs to amplify HIV infection was not specific to the viral strain. We observed that DC amplification of T cell infection occurred with various CXCR4-tropic, CCR5-tropic, dual-tropic, and transmitted founder strains (**Supplementary Fig. 3**).

### **DC-T cell transmission of HIV is drug-resistant**

We next asked whether DC amplification of T cell infection leads to anti-retroviral drug insensitivity. We compared T cell infection in DC-free culture and DC-T cell coculture in the presence or absence of the reverse transcriptase inhibitor Tenofovir. We found that T cell infection decreased precipitously in the DC-free culture compared to DC-T cell coculture (**Fig. 2a**). We previously quantified T cell infection sensitivity to drugs using the transmission index ( $T_x$ ), which is the fraction of T cells infected in the presence of drug divided by the fraction of T cells infected in the absence of drug (Sigal et al., 2011). Drug insensitivity ( $T_x$ ) is dependent on the number of infectious particles transmitted to the target T cells. Thus, if the multiplicity of infection (m.o.i) of the target T cell is low, then infection is sensitive to the effect of drugs and  $T_x$  will be  $\ll 1$ . Alternatively, if the m.o.i. is high, then infection is insensitive to the effect of drugs and  $T_x$  will approach 1. We found the  $T_x$  in DC-T coculture was 4-fold higher compared to DC-free culture (**Fig. 2b**), suggesting that the ability of DCs to concentrate and transmit a high number of virions to a target T cells results in a relatively drug-insensitive mode of infection.

### **DC-T cell transmission requires cell-to-cell contact**

We next determined if amplification of T cell infection and drug insensitivity was dependent on cell-to-cell contact between DCs and T cells. We found amplification (**Fig. 3a**) and drug insensitivity (**Fig. 3a,b**) of T cell infection were abolished if DCs and T cells were physically separated by a transwell membrane. These data suggest drug-insensitivity associated with DC-to-T cell infection is due to the DC's ability to concentrate and transmit virions to T cell through physical interactions.

### **Virus input is important to DC-T cell transmission**

We next sought to determine the effect of virus input on drug insensitivity. Despite increasing the amount of NL4-3 added to DC-free culture,  $T_X$  was unaffected (**Fig. 4**). However, as the virus input was increased in DC-T cell cocultures, the  $T_X$  also increased, indicating DC-to-T cell transmission is dependent on the amount of virus in the system. These results suggest that the drug insensitivity of DC-to-T cell transmission is directly related to the amount of virions available for capture and transmission by DCs.

## **DISCUSSION**

In our previous work we found that cell-to-cell transmission between an infected donor T cell and an uninfected T cell target was a high multiplicity of infection, which allowed for ongoing replication in the presence of anti-retroviral drug (Sigal et al., 2011). Others have also found cell-to-cell transmission to be dependent on high local concentrations of virus particles at sites of cellular contacts (Monel et al., 2012). In this report, we examined cell-to-cell transmission of HIV between DCs and T cells and asked whether this mode of transmission would allow replication in the presence of anti-retroviral drug. We found that DCs were essential to two processes. First, consistent with previous work, we found DCs were difficult to infect and their infection was not required for robust

amplification of T cell infection (Granelli-Piperno et al., 1999). This DC-mediated enhancement of T cell infection was entirely dependent on cell-to-cell contact. Second, DC-to-T cell infection displayed reduced sensitivity to anti-retroviral drug and also required physical contact between the donor DCs and target T cells. We further found that drug insensitivity of DC-to-T cell transmission increased as the virus input was increased. In contrast, the amount of virus in the system had no effect on drug insensitivity of DC-free T cell infection. These results suggest that DCs can efficiently capture virions and direct them to T cell targets, which leads to amplification of T cell infection and anti-retroviral drug insensitivity. Without DCs, primary T cell infection is a very inefficient process.

Our findings raise important questions regarding the importance of DCs in the cell-to-cell spread of HIV. During initial infection, DCs are among the first immune cells to encounter HIV at mucosal surfaces (Wu and KewalRamani, 2006). It is possible that DCs carry virions back to lymphoid organs where DC-to-T cell transmission plays an important mode of spreading the virus. The contribution of DCs to the viral reservoir is under investigation. Others have found follicular DCs capture infectious virus for days and transmit them to T cells, suggesting a possible cellular virus reservoir (Keele et al., 2008).

We suspect the mode of viral transmission may also be an important factor contributing to the viral reservoir. The high multiplicity of infection associated with cell-to-cell infection allows for anti-retroviral drug insensitivity, which leads to active replication (Sigal et al., 2011). This may be especially problematic in certain anatomical niches such as lymphoid tissue, which are conducive to cell-to-cell interactions and have been found to also have reduced anti-retroviral drug level (Fletcher et al., 2014). Thus, DC-to-

T cell transmission may have real implications for persistent virus replication and reservoir replenishment *in vivo*. It is interesting to speculate whether cell-to-cell transmission of HIV contributes to low-level viremia in HIV-infected patients on anti-retroviral therapy. Altogether, if the viral reservoir is to be eradicated, then a deeper understanding of factors contributing to its formation and maintenance is required.

## **EXPERIMENTAL PROCEDURES**

**Antibodies and Flow cytometry.** Single-cell suspensions were stained with the following antibodies from Biolegend: PE-anti-human CD11c (301606), PerCP-anti-human CD14 (325621), APC-anti-human CD86 (305411), and APC/Cy7-anti-human HLA-DR (307617). For dead cell staining, 1 $\mu$ g ml<sup>-1</sup> of propidium iodine was added. Cells were analyzed on a MACSQuant analyzer (Miltenyi), and data were analyzed with FlowJo software (TreeStar).

**Generation of DCs.** Human moDCs were generated by culture for 7 d of CD14<sup>+</sup> peripheral blood monocytes (UCLA Center for AIDS Research (CFAR) Virology Core Lab) in media containing human GM-CSF and IL-4 (Peprotech). DCs were cultured in RPMI-1640 medium supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Sigma), 1% (vol/vol) non-essential amino acids (HyClone), 1mM sodium pyruvate (Gibco), 10mM HEPES (Gibco), and 0.05mM 2-mercaptoethanol (Gibco).

**Virus Production.** The pNL4-3 plasmid used to generate infectious HIV-1 was obtained from the AIDS Reagent Program, Division of AIDS, NIAID, NIH. Virus was prepared by culturing HEK293T/17 cells in 10-cm tissue culture dishes and transfecting with BioT (Bioland Scientific, Paramount CA) according to manufacturer's instructions using a total of 10  $\mu$ g DNA pMDLg/pRRE and pRSV-Rev. All viral supernatants were harvested at 36,

48, and 60 h post-transfection and filtered through a 0.45- $\mu$ m filter. The concentration of gag was measured by p24 capture ELISA Kit (ImmunoDiagnostics).

**Statistical Analyses.** GraphPad Prism 6.0 software was used for data analysis. Statistical significance was determined by unpaired, two-sided Student's *t*-tests for two groups or one-way ANOVA (with post-hoc Tukeys' multiple comparison test) for three or more groups.

## FIGURE LEGENDS

**Figure 1. DCs significantly amplify T cell infection.** (a) Infection of PBMCs with (center) or without DCs (left) in co-culture was analyzed by flow cytometry. Uninfected DC-T coculture (right) was included as a negative control. Number in the top right gate indicates percentage of infected T cells. (b) Percentages of p24<sup>+</sup> T cells were measured in infected DC-free culture or DC-T cell co-culture. Each symbol represents one donor. Mean  $\pm$  s.e.m ( $\eta$  = 6 donors). Data is representative of six independent experiments (a) or pooled from six independent experiments (b).

**Figure 2. DC-T cell infection is drug-resistant.** (a) Infection of DC-free PBMCs (left two plots) or DC-T cell co-culture (right two plots) in the absence of presence of 10 $\mu$ m of TFV. (b) Transmission index when infection occurs in DC-free culture (blue bars or squares) or DC-T cell coculture. TFV at 0  $\mu$ M, 5  $\mu$ M, 10  $\mu$ M (wedges). Mean  $\pm$  s.e.m ( $\eta$  = 3 donors). Data is from one experiment (a,b).

**Figure 3. DC-T cell drug resistance depends on physical contact between cells.** (a) Infection of DC-free PBMCs or DC-T cell co-culture with (bottom) or without (top) a transwell system, in which DCs are physically separated from PBMCs by a transwell membrane. Infection occurs in the absence of presence of 10 $\mu$ m of TFV. (b) Transmission index when infection occurs in DC-free culture or DC-T cell coculture with or without 10  $\mu$ M of TFV in the absence of presence of a transwell system. Mean  $\pm$  s.e.m ( $\eta$  = 3 donors). Data is from one experiment (a,b).

**Figure 4. DC-to-T cell transmission is dependent on the amount of virus in the system.** DC-free culture (left) or DC-T cell co-culture (right) were infected with varying amounts of NL4-3 in the absence of presence of 10 $\mu$ m of TFV. x-axis is ng of p24 of

NL4-3.  $\gamma$ -axis is the transmission index. Each symbol represents a donor. Data is representative of one experiment.

## REFERENCES

- CAMERON, P. U., FREUDENTHAL, P. S., BARKER, J. M., GEZELTER, S., INABA, K. & STEINMAN, R. M. 1992. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4<sup>+</sup> T cells. *Science*, 257, 383-7.
- DONG, C., JANAS, A. M., WANG, J. H., OLSON, W. J. & WU, L. 2007. Characterization of human immunodeficiency virus type 1 replication in immature and mature dendritic cells reveals dissociable cis- and trans-infection. *J Virol*, 81, 11352-62.
- FELTS, R. L., NARAYAN, K., ESTES, J. D., SHI, D., TRUBEY, C. M., FU, J., HARTNELL, L. M., RUTHEL, G. T., SCHNEIDER, D. K., NAGASHIMA, K., BESS, J. W., JR., BAVARI, S., LOWEKAMP, B. C., BLISS, D., LIFSON, J. D. & SUBRAMANIAM, S. 2010. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. *Proc Natl Acad Sci U S A*, 107, 13336-41.
- FLETCHER, C. V., STASKUS, K., WIETGREFE, S. W., ROTHENBERGER, M., REILLY, C., CHIPMAN, J. G., BEILMAN, G. J., KHORUTS, A., THORKELSON, A., SCHMIDT, T. E., ANDERSON, J., PERKEY, K., STEVENSON, M., PERELSON, A. S., DOUEK, D. C., HAASE, A. T. & SCHACKER, T. W. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proc Natl Acad Sci U S A*, 111, 2307-12.
- GRANELLI-PIPERNO, A., FINKEL, V., DELGADO, E. & STEINMAN, R. M. 1999. Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. *Curr Biol*, 9, 21-9.
- IZQUIERDO-USEROS, N., LORIZATE, M., MCLAREN, P. J., TELENTI, A., KRAUSSLICH, H. G. & MARTINEZ-PICADO, J. 2014. HIV-1 capture and transmission by dendritic cells: the role of viral glycolipids and the cellular receptor Siglec-1. *PLoS Pathog*, 10, e1004146.
- JOLLY, C., WELSCH, S., MICHOR, S. & SATTENTAU, Q. J. 2011. The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. *PLoS Pathog*, 7, e1002226.
- KEELE, B. F., TAZI, L., GARTNER, S., LIU, Y., BURGON, T. B., ESTES, J. D., THACKER, T. C., CRANDALL, K. A., MCARTHUR, J. C. & BURTON, G. F. 2008. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. *J Virol*, 82, 5548-61.
- MCDONALD, D., WU, L., BOHKS, S. M., KEWALRAMANI, V. N., UNUTMAZ, D. & HOPE, T. J. 2003. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. *Science*, 300, 1295-7.
- MONEL, B., BEAUMONT, E., VENDRAME, D., SCHWARTZ, O., BRAND, D. & MAMMANO, F. 2012. HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores. *J Virol*, 86, 3924-33.
- SATTENTAU, Q. 2008. Avoiding the void: cell-to-cell spread of human viruses. *Nat Rev Microbiol*, 6, 815-26.

- SATTENTAU, Q. J. 2011. The direct passage of animal viruses between cells. *Curr Opin Virol*, 1, 396-402.
- SIGAL, A. & BALTIMORE, D. 2012. As good as it gets? The problem of HIV persistence despite antiretroviral drugs. *Cell Host Microbe*, 12, 132-8.
- SIGAL, A., KIM, J. T., BALAZS, A. B., DEKEL, E., MAYO, A., MILO, R. & BALTIMORE, D. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. *Nature*, 477, 95-8.
- WU, L. & KEWALRAMANI, V. N. 2006. Dendritic-cell interactions with HIV: infection and viral dissemination. *Nat Rev Immunol*, 6, 859-68.


## **SUPPLEMENTARY FIGURE LEGENDS**

**Supplementary Figure 1. LPS activation of monocyte-derived DCs.** DCs were treated with LPS and analyzed by flow cytometry. (a) Number in the top left gate indicates percentage of cells with the DC phenotype CD14<sup>+</sup>DC-SIGN<sup>+</sup>. (b) The surface expression of activation markers CD86 and HLA-DR were analyzed. Data is representative of two independent experiments.


**Supplementary Figure 2. DC amplification of HIV infection of T cells in six donors.** Infection of PBMCs in the presence or absence of DCs was analyzed by flow cytometry. Percentages of infected p24<sup>+</sup> T cells were measured in six donors. Each symbol represents a technical replicate. Horizontal bar indicates the mean. Data is representative of six independent experiments.

**Supplementary Figure 3. DC amplification of T cell infection with different HIV-1 strains.** Infection of PBMCs with or without DCs by CXCR4-tropic (LAI), CCR5 tropic (JRCSF, NFNSX), dual-tropic (89.6) and CCR5-tropic founder strains (11745, 11739) were analyzed by flow cytometry. Number in the top right gate indicates percentage of infected T cells.


## FIGURES




**Figure 1. DCs significantly amplify T cell infection.**



**Figure 2. DC-T cell infection is drug-resistant.**




**Figure 3. DC-T cell drug resistance depends on physical contact between cells.**




**Figure 4. DC-to-T cell transmission is dependent on the amount of virus in the system.**


**a**




**b**



Supplementary Figure 1. LPS activation of monocyte-derived DCs.



Supplementary Figure 2. DC amplification of HIV infection of T cells in six donors.



Supplementary Figure 3. DC amplification of T cell infection with different HIV-1 strains.

## **Chapter 4: Conclusions and Future Directions**

## **CONCLUSIONS**

In this thesis I have uncovered that antigenic protein can be delivered by viral particles via pseudotransduction. This mechanism of protein delivery is sufficient to generate antigen-specific immune responses in a mouse model. Further, I have found that human DNA is a component of viral particles and acts as a viral ligand to stimulate the host innate immune STING-dependent pathway. The overall significance, innovation, and future directions of these findings are explored in this chapter.

## **SIGNIFICANCE**

**Importance of developing novel vaccine approaches.** Over the past two centuries, vaccines have led to some of the most important public health achievements including the worldwide eradication of smallpox and near-elimination of polio (Henderson, 2011). In addition to protecting against pathogens, some of the current vaccines can also prevent against certain types of cancers of the liver and cervix (Ungaro et al., 2013). However, there are many pathogens such as HIV, malaria, and tuberculosis, as well as cancers, for which the development of effective vaccines has been difficult. This difficulty is partly due to the fact that intracellular pathogens and cancers require robust antigen-specific CD8<sup>+</sup> T cell for protection (Wong and Pamer, 2003). A protein subunit vaccine, which involves the direct administration of a specific protein from a pathogen, is poor at generating CD8<sup>+</sup> T cells (Chackerian, 2007). The viral-like particle (VLP) is a type of subunit vaccine, which is much more effective at eliciting cell-mediated immune responses than other subunit vaccines. They are constructed from few viral proteins and lack a viral genome. Despite their simplified nature, VLPs infect cells in a highly immunostimulatory fashion, thereby generating antigen-specific CD8<sup>+</sup> T responses to their viral proteins. In addition, VLPs are a safer alternative than live-attenuated vaccines composed of modified forms of entire microbes with reduced pathogenicity, which can be lethal to immunocompromised patients and potentially revert to virulent strains. As a consequence, there is a significant need for the development of alternative vaccines to target pathogens for which natural protection is inefficient.

**Importance of developing future virus-like particle (VLP) vaccines.** One important future line of research involves the development of recombinant VLPs which capitalize on the immunogenic nature of VLPs to deliver the antigens of heterologous pathogens. This type of format could greatly simplify future vaccine design and production. In particular, current vaccine manufacturing is complex, involving diverse culture systems ranging from mammalian cell lines to insect cell lines, and sometimes employing yeast, plant cells, or fertilized chicken eggs (Lua et al., 2014). Significant resources are expended in the development, validation, and elucidation of the mechanism for each type of VLP. Thus, it is important to explore and develop strategies in which a single culture system can generate a broad armament of vaccines against different intracellular pathogens and cancers.

**Critical barrier to the use of VLPs as vaccines.** Understanding the mechanism by which VLPs exert their immunostimulatory effect has been a barrier to their use. These genome-less vectors do not contain nucleic acids, which are generally thought to be important in stimulating innate immune sensors (Akira et al., 2006, Breckpot et al., 2007, Luban, 2012). Nevertheless, genome-less VLPs do trigger innate responses, presumably through interactions of their viral proteins. The identification of the immunostimulatory VLP proteins and their corresponding innate immune sensing pathways might provide important mechanistic insights with the potential to influence future VLP or adjuvant designs.

**Potential to understand mechanisms of vaccination and create improved vaccination platforms.** If the proposed aims are achieved, we will have created a highly flexible and simplified method of producing recombinant VLPs with enhanced efficacy. Furthermore, we will also have gained an understanding of the mechanisms by which VLPs exert their immunostimulatory effect and quantified host immune responses. Collectively, successful completion of this proposal could be fundamentally important to future vaccine development by expanding our knowledge of viral mechanisms and host responses to infection.

## **INNOVATION**

The current work is innovative in the following ways. First, we have discovered an immune mechanism used by LVs and VLPs which has identified a previously unknown innate immune sensing pathway. We have found that viral particles encapsulate human DNA, which serves to stimulate the host STING pathway. Secondly, this work explores the use of a dendritic cell (DC)-targeting VLPs, which have not been previously described. The DC-targeting Sindbis virus-derived envelope has been used to specifically direct viral vectors to DCs, which are among the most important antigen-presenting cell of the immune system (Yang et al., 2008, Xiao et al., 2012, Dai et al., 2009). In this work we have developed a highly efficient DC-targeting VLP. Thirdly, we have improved upon the production methods for producing recombinant VLPs delivering heterologous antigens from human cell lines. Currently, recombinant VLPs are made by fusing heterologous antigens to the viral proteins of the VLP (Roose et al., 2013, Stoute et al., 1997, Neiryneck et al., 1999, Vietheer et al., 2007, Arora et al., 2013, Kaczmarczyk et al., 2011, Gheysen et al., 1989). However, the immunodominant epitope may not be known or more than one may be required for protection. Furthermore, fusion of epitopes to viral proteins may disrupt the ability of VLPs to self-assemble into particles. In this thesis we provide an innovative and simple method for incorporating whole heterologous proteins into VLPs. Lastly, this work has generated easy ways to produce immunostimulatory vectors and investigate new fundamentally important mechanisms of immunity.

## **FUTURE DIRECTIONS**

These interesting findings lead to further questions about pseudotransduction and human DNA-mediated immune stimulation.

- 1) How does heterologous protein and human DNA get encapsulated into viral particles? Is the mechanism of encapsulation passive or directed?
- 2) What is the characterization of human nucleic acids in the viral particles? What is the genetic landscape of dsDNA represented in these viral particles? Is the whole human genome represented randomly or non-randomly? Are there ssDNA as well, which may be

important to immune stimulation? Are there human RNA molecules which may also have an immunostimulatory function? Is this process of protein and DNA encapsulation generalizable to other viruses and cell types? Our results suggest this process is not specific to the transfection process or 293T cells. Does the viral envelope of HIV also induce DC activation similarly to the viral envelope from VSV and Sindbis virus?

- 3) Viral particles are known to represent a heterogeneous population of particles. Do the particles differ by heterologous protein and human DNA composition? Are there methods to separate particles based on these components?
- 4) What is the innate immune sensor that detects human DNA released via viral fusion into the cytoplasm? Various cytosolic DNA sensors signal through the STING-dependent pathway. It is unclear which of the putative DNA cytosolic sensors are involved in LV detection. In particular, is the dsDNA cytosolic sensor cGAS involved in LV or VLP-mediated DC stimulation?
- 5) It appears that viral fusion itself also stimulates DCs in a STING-independent method. What is the mechanism of this STING-independent process?
- 6) What role does cell death play in LV-mediated immune stimulation? Do LV-treated cells die by apoptosis? If so, is autophagy involved?
- 7) Can DC-targeting VLPs be used as an effective vaccine? Can these VLPs protect against infectious challenges of intracellular pathogens such as *Listeria* or LCMV, which required potent memory CD8<sup>+</sup> T cell responses?

## REFERENCES

- AKIRA, S., UEMATSU, S. & TAKEUCHI, O. 2006. Pathogen recognition and innate immunity. *Cell*, 124, 783-801.
- ARORA, U., TYAGI, P., SWAMINATHAN, S. & KHANNA, N. 2013. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. *Vaccine*, 31, 873-878.
- BRECKPOT, K., EMEAGI, P., DULLAERS, M., MICHIELS, A., HEIRMAN, C. & THIELEMANSI, K. 2007. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. *Human Gene Therapy*, 18, 536-546.
- CHACKERIAN, B. 2007. Virus-like particles-flexible platforms for vaccine development. *Expert Review of Vaccines*, 6, 381-390.
- DAI, B. B., YANG, L., YANG, H. G., HU, B. L., BALTIMORE, D. & WANG, P. 2009. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.

- Proceedings of the National Academy of Sciences of the United States of America*, 106, 20382-20387.
- GHEYSEN, D., JACOBS, E., DEFORESTA, F., THIRIART, C., FRANCOITTE, M., THINES, D. & DEWILDE, M. 1989. Assembly and Release of Hiv-1 Precursor Pr55gag Virus-Like Particles from Recombinant Baculovirus Infected Insect Cells. *Cell*, 59, 103-112.
- HENDERSON, D. A. 2011. The eradication of smallpox - An overview of the past, present, and future. *Vaccine*, 29, D7-D9.
- KACZMARCZYK, S. J., SITARAMAN, K., YOUNG, H. A., HUGHES, S. H. & CHATTERJEE, D. K. 2011. Protein delivery using engineered virus-like particles. *Proceedings of the National Academy of Sciences of the United States of America*, 108, 16998-17003.
- LUA, L. H. L., CONNORS, N. K., SAINSBURY, F., CHUAN, Y. P., WIBOWO, N. & MIDDELBERG, A. P. J. 2014. Bioengineering Virus-Like Particles as Vaccines. *Biotechnology and Bioengineering*, 111, 425-440.
- LUBAN, J. 2012. Innate Immune Sensing of HIV-1 by Dendritic Cells. *Cell Host & Microbe*, 12, 408-418.
- NEIRYNCK, S., DEROO, T., SAELENS, X., VANLANDSCHOOT, P., JOU, W. M. & FIERS, W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. *Nature Medicine*, 5, 1157-1163.
- ROOSE, K., DE BAETS, S., SCHEPENS, B. & SAELENS, X. 2013. Hepatitis B core-based virus-like particles to present heterologous epitopes. *Expert Review of Vaccines*, 12, 183-198.
- STOUTE, J. A., SLAOU, M., HEPNER, D. G., MOMIN, P., KESTER, K. E., DESMONS, P., WELDE, B. T., GARCON, N., KRZYCH, U., MARCHAND, M., BALLOU, W. R. & COHEN, J. D. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum* malaria. *New England Journal of Medicine*, 336, 86-91.
- UNGARO, F., CONTE, C., QUAGLIA, F., TORNESELLO, M. L., BUONAGURO, F. M. & BUONAGURO, L. 2013. VLPs and particle strategies for cancer vaccines. *Expert Review of Vaccines*, 12, 1173-1193.
- VIETHEER, P. T., BOO, I., DRUMMER, H. E. & NETTER, H. J. 2007. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. *Antiviral Therapy*, 12, 477-487.
- WONG, P. & PAMER, E. G. 2003. Cd8 T cell responses to infectious pathogens. *Annual Review of Immunology*, 21, 29-70.
- XIAO, L., KIM, J., LIM, M., DAI, B. B., YANG, L. L., REED, S. G., BALTIMORE, D. & WANG, P. 2012. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. *Vaccine*, 30, 2570-2581.
- YANG, L., YANG, H., RIDEOUT, K., CHO, T., IL JOO, K., ZIEGLER, L., ELLIOT, A., WALLS, A., YU, D., BALTIMORE, D. & WANG, P. 2008. Engineered lentivector targeting of dendritic cells for in vivo immunization. *Nature Biotechnology*, 26, 326-334.